HK1248731A1 - Immunoglobulin variants and uses thereof - Google Patents

Immunoglobulin variants and uses thereof Download PDF

Info

Publication number
HK1248731A1
HK1248731A1 HK18108517.7A HK18108517A HK1248731A1 HK 1248731 A1 HK1248731 A1 HK 1248731A1 HK 18108517 A HK18108517 A HK 18108517A HK 1248731 A1 HK1248731 A1 HK 1248731A1
Authority
HK
Hong Kong
Prior art keywords
antibody
cells
antibodies
binding
antigen
Prior art date
Application number
HK18108517.7A
Other languages
English (en)
Chinese (zh)
Inventor
W Adams Camellia
C Chan Andrew
W Crowley Craig
B Lowman Henry
R Nakamura Gerald
G Presta Leonard
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32685285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1248731(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of HK1248731A1 publication Critical patent/HK1248731A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
HK18108517.7A 2002-12-16 2018-07-03 Immunoglobulin variants and uses thereof HK1248731A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43411502P 2002-12-16 2002-12-16
US434115P 2002-12-16
US52616303P 2003-12-01 2003-12-01
US526163P 2003-12-01

Publications (1)

Publication Number Publication Date
HK1248731A1 true HK1248731A1 (en) 2018-10-19

Family

ID=32685285

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18108517.7A HK1248731A1 (en) 2002-12-16 2018-07-03 Immunoglobulin variants and uses thereof

Country Status (35)

Country Link
US (7) US7799900B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (5) EP2289936B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (3) JP4351674B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (2) KR20070055625A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN103833854B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (3) AR042485A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE470675T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2003301079C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2018C021I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (2) BRPI0316779B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2507898C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2008003323A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CR (2) CR7875A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (2) CY1110759T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE60332957D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK1572744T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2633311T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR18C1023I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1248731A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20050649B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (3) HU227217B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL168754A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA27704A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA05006511A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO338402B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ566907A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL212899B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1572744E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (2) RS20100366A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2326127C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG2013036975A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (2) SI1572744T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (2) TWI335821B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA89350C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2004056312A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (1081)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
WO2000009160A1 (en) 1998-08-11 2000-02-24 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
TR200101302T2 (tr) * 1998-11-09 2001-10-22 Idec Pharmaceuticals Corporation BMT yada PBSC transplantı alan hastalarda in vitro ya da in vivo temizleyici madde olarak kimerik anti-CD20 antikorunun kullanımı.
DE69942727D1 (de) 1998-11-09 2010-10-14 Biogen Idec Inc Chimärer anti-CD20 Antikörper, Rituxan, zur Verwendung in der Behandlung der chronischen lymphatischen Leukemie
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
PL200134B1 (pl) * 1999-05-07 2008-12-31 Genentech Inc Zastosowanie przeciwciała anty-CD20
PL201086B1 (pl) * 1999-07-12 2009-03-31 Genentech Inc Zastosowanie przeciwciał wiążących się z antygenem CD20
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
JP2004508420A (ja) * 2000-09-18 2004-03-18 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
ES2326964T3 (es) * 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
JP2006512891A (ja) * 2002-04-18 2006-04-20 ジェネンコー・インターナショナル・インク 糸状菌における機能性抗体の生産
JP4351674B2 (ja) * 2002-12-16 2009-10-28 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体とその使用法およびその使用
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
WO2004091657A2 (en) * 2003-04-09 2004-10-28 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
BRPI0411276A (pt) * 2003-06-05 2006-08-01 Genentech Inc métodos de esgotamento de células b, método de tratamento de neoplasma de células b ou malignidade, método de alìvio de disfunção autoimunológica regulada por células b, composição e artigo industrializado
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
HRP20100303T1 (hr) 2003-11-05 2010-07-31 Roche Glycart Ag Cd20 antitijela s povećanim afinitetom vezivanja fc receptora i efektorskim djelovanjem
WO2005063815A2 (en) * 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
EP2053062A1 (en) 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
MXPA06014067A (es) * 2004-06-04 2007-02-15 Genentech Inc Metodo para tratar lupus.
BRPI0510915A (pt) * 2004-06-04 2007-11-13 Genentech Inc método para o tratamento da esclerose múltipla e artigo manufaturado
JP2008504289A (ja) * 2004-06-25 2008-02-14 メディミューン，インコーポレーテッド 部位特異的突然変異誘発による哺乳動物細胞における組換え抗体の産生の増加
WO2006085967A2 (en) * 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
US20060062787A1 (en) * 2004-07-22 2006-03-23 Genentech, Inc. Method for treating Sjogren's syndrome
WO2006020114A2 (en) 2004-08-04 2006-02-23 Applied Molecular Evolution, Inc. Variant fc regions
AU2005285347A1 (en) * 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
ZA200702335B (en) 2004-10-05 2009-05-27 Genentech Inc Method for treating vasculitis
SV2006002258A (es) * 2004-10-08 2006-09-19 Wyeth Corp Inmunoterapia de trastornos autoinmunes
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP2325206B1 (en) 2004-11-12 2014-03-19 Xencor, Inc. Fc variants with altered binding to fcrn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
FR2879204B1 (fr) 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
BRPI0519420A2 (pt) 2004-12-28 2009-01-20 Innate Pharma anticorpo, composiÇço, mÉtodos para reconstituiÇço de lise mediada por cÉlula nk de uma cÉlula alvo em uma populaÇço, para avaliaÇço de um anticorpo contra nkg2a de humano, para produÇço de um anticorpo, para identificaÇço de um regime de administraÇço adequado para um anticorpo terapÊutico, para matanÇa de uma cÉlula nk, reduÇço da atividade de uma cÉlula nk, reduÇço da proliferaÇço de cÉlulas nk, prevenÇço da lise de cÉlulas suscetÍveis À lise por cÉlula nk, ou reduÇço do némero de cÉlulas nk em uma populaÇço, e para detecÇço da ligaÇço de um anticorpo em nkg2a, uso de uma composiÇço, conjugado, e, kit
RU2007130688A (ru) * 2005-01-13 2009-02-20 Дженентек, Инк. (Us) Способ лечения
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
CA2605697A1 (en) * 2005-04-26 2006-11-02 Bioren, Inc. Method of producing human igg antibodies with enhanced effector functions
RU2007147426A (ru) 2005-05-20 2009-06-27 Дженентек, Инк. (Us) Предварительная обработка биологического образца, взятого у индивидуума с аутоиммунным заболеванием
US20070014720A1 (en) * 2005-06-02 2007-01-18 Gadi Gazit-Bornstein Antibodies directed to CD20 and uses thereof
PL1912675T3 (pl) 2005-07-25 2014-10-31 Emergent Product Dev Seattle Zmniejszanie liczby komórek B za pomocą cząsteczek wiążących swoistych dla antygenów CD37 i CD20
US20090226440A1 (en) * 2005-08-12 2009-09-10 Shane Grey Prophylactic and/or Therapeutic Method for Treatment of Autoimmune Disease
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2624189A1 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
JP4860703B2 (ja) 2005-10-06 2012-01-25 ゼンコー・インコーポレイテッド 最適化された抗ｃｄ３０抗体
ES2616316T3 (es) 2005-10-11 2017-06-12 Amgen Research (Munich) Gmbh Composiciones que comprenden anticuerpos específicos para diferentes especies y usos de los mismos
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
EP1952150B1 (en) 2005-11-23 2016-12-14 Genentech, Inc. Methods and compositions related to b cell assays
AU2006342792A1 (en) 2005-12-02 2007-11-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R
ES2526204T3 (es) 2006-01-05 2015-01-08 Genentech, Inc. Anticuerpos anti-EphB4 y métodos para usar los mismos
CN103193885B (zh) 2006-01-20 2015-05-13 健泰科生物技术公司 抗ephrinb2抗体及其使用方法
WO2007102200A1 (ja) * 2006-03-07 2007-09-13 Osaka University 抗ｃｄ２０モノクローナル抗体
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
CN103030696B (zh) 2006-05-30 2016-09-28 健泰科生物技术公司 抗体和免疫偶联物及其用途
SG175615A1 (en) 2006-06-06 2011-11-28 Genentech Inc Anti-dll4 antibodies and methods using same
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
PT2426150T (pt) 2006-06-30 2018-01-22 Novo Nordisk As Anticorpos anti-nkg2a e utilizações dos mesmos
EP2046383B1 (en) 2006-07-04 2014-11-19 Genmab A/S Cd20 binding molecules for the treatment of copd
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
US20100166741A1 (en) * 2006-07-13 2010-07-01 Genentech , Inc. Altered br-3 binding polypeptides
WO2008011081A2 (en) 2006-07-19 2008-01-24 The Trustees Of The University Of Pennsylvania Wsx-1/p28 as a target for anti-inflammatory responses
SI2059536T1 (sl) 2006-08-14 2014-06-30 Xencor, Inc. Optimirana protitelesa, ki ciljajo CD19
WO2008034076A2 (en) * 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
AU2007299843B2 (en) 2006-09-18 2012-03-08 Xencor, Inc Optimized antibodies that target HM1.24
CA2665644A1 (en) 2006-10-12 2008-05-29 Genentech, Inc. Antibodies to lymphotoxin-alpha
ES2387924T3 (es) 2006-10-27 2012-10-04 Genentech, Inc. Anticuerpos e inmunoconjugados y usos para los mismos
HUE041957T2 (hu) 2006-12-01 2019-06-28 Novartis Ag Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US20100267933A1 (en) 2006-12-21 2010-10-21 Moya Wilson Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
EP2377527B1 (en) 2007-01-22 2013-07-17 Genentech, Inc. Polyelectrolyte precipitation and purification of antibodies
JP2010518115A (ja) 2007-02-09 2010-05-27 ジェネンテック， インコーポレイテッド 抗Ｒｏｂｏ４抗体およびそれらのための使用
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
HRP20160730T1 (hr) * 2007-06-25 2016-07-15 Esbatech, An Alcon Biomedical Research Unit Llc Metode modificiranja antitijela i modificirana antitijela s poboljšanim funkcionalnim svojstvima
CN101842388B (zh) 2007-09-13 2013-09-04 德勒尼克斯治疗股份公司 针对β淀粉样肽的人源化抗体
GB0718684D0 (en) * 2007-09-24 2007-10-31 Roche Products Ltd Treatment method
CA3222170A1 (en) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
EP2211903A4 (en) 2007-10-17 2011-07-06 Nuvelo Inc CLL-1 ANTIBODY
SI2840090T1 (en) 2007-10-30 2018-05-31 Genentech, Inc. Purification of the antibody by cation exchange chromatography
MX373155B (es) 2007-11-07 2020-04-21 Genentech Inc Composiciones y metodos para el tratamiento de trastornos microbianos.
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
CA2703997C (en) 2007-12-26 2017-04-04 Xencor, Inc. Fc variants with altered binding to fcrn
KR20100110864A (ko) * 2008-01-24 2010-10-13 노보 노르디스크 에이/에스 인간화된 항-인간 ｎｋｇ2ａ 모노클로날 항체
TWI532498B (zh) 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
JP5547709B2 (ja) * 2008-03-25 2014-07-16 ロシュ グリクアート アクチェンゲゼルシャフト 非−ホジキンリンパ腫の治療のための、シクロホスファミド、ビンクリスチン及びドキソルビシンと組み合わせた、増加した抗体依存性細胞障害活性（ａｄｃｃ）を有するｉｉ型抗−ｃｄ２０抗体の使用
SG189772A1 (en) 2008-04-11 2013-05-31 Trubion Pharmaceuticals Inc Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
EP2899209A1 (en) * 2008-04-29 2015-07-29 Abbvie Inc. Dual Variable Domain Immunoglobulins and uses thereof
UY31861A (es) * 2008-06-03 2010-01-05 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
KR20110016958A (ko) * 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
US8822645B2 (en) * 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
DK2318832T3 (da) 2008-07-15 2014-01-20 Academia Sinica Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder
PT3604324T (pt) 2008-08-14 2024-05-10 Genentech Inc Métodos para remover um contaminante com a utilização de cromatografia de membrana de permuta iónica de deslocação de proteína indígena
MX2011002372A (es) 2008-09-10 2011-04-04 Genentech Inc Composiciones y metodos para la prevencion de la degradacion oxidativa de proteinas.
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
KR102100066B1 (ko) 2008-10-14 2020-04-10 제넨테크, 인크. 이뮤노글로불린 변이체 및 그의 용도
TW201021831A (en) * 2008-11-17 2010-06-16 Genentech Inc Method and formulation for reducing aggregation of a macromolecule under physiological conditions
NZ593641A (en) 2008-12-09 2013-01-25 Halozyme Inc Extended soluble ph20 polypeptides and uses thereof
WO2010074953A1 (en) 2008-12-16 2010-07-01 Millipore Corporation Stirred tank reactor and method
BRPI0923034A2 (pt) 2008-12-17 2015-12-15 Genentech Inc terapia de combinação para virus da hepatite c
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP2382234A2 (en) 2008-12-23 2011-11-02 Genentech, Inc. Immunoglobulin variants with altered binding to protein a
AU2010214082A1 (en) * 2009-02-16 2011-10-13 Synthon Biopharmaceuticals B.V. Humanized anti-CD20 antibodies and methods of use
CA2752884A1 (en) 2009-02-27 2010-09-02 Genentech, Inc. Methods and compositions for protein labelling
MA33198B1 (fr) 2009-03-20 2012-04-02 Genentech Inc Anticorps anti-her di-spécifiques
CN103755808B (zh) 2009-03-25 2016-02-10 霍夫曼-拉罗奇有限公司 抗-α5β1抗体及其应用
KR101822663B1 (ko) 2009-03-25 2018-01-29 제넨테크, 인크. 항-ｆｇｆｒ３ 항체 및 그의 사용 방법
AR075982A1 (es) 2009-03-31 2011-05-11 Roche Glycart Ag Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion
JP5616428B2 (ja) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト 三価の二重特異性抗体
EP2427479B1 (en) 2009-05-07 2018-11-21 The Regents of The University of California Antibodies and methods of use thereof
US20120121578A1 (en) * 2009-05-13 2012-05-17 Gliknik Inc. Methods of using immunoglobulin aggregates
US8815242B2 (en) * 2009-05-27 2014-08-26 Synageva Biopharma Corp. Avian derived antibodies
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
AR077595A1 (es) 2009-07-27 2011-09-07 Genentech Inc Tratamientos de combinacion
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
SG178177A1 (en) 2009-07-31 2012-03-29 Genentech Inc Inhibition of tumor metastasis using bv8- or g-csf-antagonists
TWI409079B (zh) 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
AU2010281867A1 (en) 2009-08-14 2012-02-02 Roche Glycart Ag Combination therapy of an afucosylated CD20 antibody with fludarabine and/or mitoxantrone
MX2012002651A (es) * 2009-09-01 2012-05-22 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
ES2599076T3 (es) 2009-09-02 2017-01-31 Genentech, Inc. Smoothened mutante y métodos de utilización del mismo
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
KR20120104517A (ko) 2009-09-03 2012-09-21 제넨테크, 인크. 류마티스 관절염의 치료, 진단 및 모니터링 방법
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
EP3009455A1 (en) * 2009-09-16 2016-04-20 Immunomedics Inc. Class i anti-cea antibodies and uses thereof
US9084743B2 (en) 2009-09-17 2015-07-21 Baxter International Inc. Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
CN102666875A (zh) * 2009-10-15 2012-09-12 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
US8435511B2 (en) 2009-10-22 2013-05-07 Genentech, Inc. Anti-hepsin antibodies and methods using same
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2496600A1 (en) 2009-11-04 2012-09-12 Fabrus LLC Methods for affinity maturation-based antibody optimization
RU2585488C2 (ru) 2009-11-05 2016-05-27 Дженентек, Инк. Способы и композиция для секреции гетерологичных полипептидов
MX343228B (es) 2009-11-30 2016-10-26 Biotest Ag Anticuerpos anti-il-10humanizados para el tratamiento de lupus sistémico eritematoso.
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
JP2013512674A (ja) 2009-12-02 2013-04-18 アクセルロン ファーマ， インコーポレイテッド Ｆｃ融合タンパク質の血清半減期を増加させるための組成物および方法
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011071577A1 (en) 2009-12-11 2011-06-16 Genentech, Inc. Anti-vegf-c antibodies and methods using same
NZ600826A (en) 2009-12-23 2014-09-26 Genentech Inc Anti-bv8 antibodies and uses thereof
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
CA2789629A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc. Cd20 antibodies and uses thereof
US20110200595A1 (en) 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
ES2519348T3 (es) 2010-02-18 2014-11-06 Genentech, Inc. Antagonistas de neurregulina y uso de los mismos en el tratamiento del cáncer
PL2550018T3 (pl) 2010-03-22 2019-08-30 F.Hoffmann-La Roche Ag Kompozycje i sposoby użyteczne do stabilizowania preparatów zawierających białko
JP6093692B2 (ja) 2010-03-24 2017-03-08 ジェネンテック， インコーポレイテッド 抗ｌｒｐ６抗体
WO2011123813A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
EP2563391B1 (en) 2010-04-27 2020-08-26 Roche Glycart AG Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
EP2566510A1 (en) 2010-05-03 2013-03-13 F. Hoffmann-La Roche AG Compositions and methods useful for reducing the viscosity of protein-containing formulations
JP5947289B2 (ja) 2010-05-10 2016-07-06 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 抗インフルエンザ活性を有するザナミビルホスホネート同族体およびインフルエンザウイルスのオセルタミビルに対する感受性の決定
TWI615405B (zh) 2010-05-14 2018-02-21 艾伯維有限公司 Ｉｌ-１結合蛋白
DK2571903T3 (da) 2010-05-17 2019-11-04 Emd Millipore Corp Polymerer, der reagerer på stimuli, til oprensning af biomolekyler
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
BR112012029866A2 (pt) 2010-06-03 2017-03-07 Genentech Inc método para a determinação da presença de uma proteína steap-1
JP5940061B2 (ja) 2010-06-18 2016-06-29 ジェネンテック， インコーポレイテッド 抗ａｘｌ抗体及び使用方法
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
CA3111727C (en) 2010-06-24 2022-07-26 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
WO2011161189A1 (en) 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use
AU2011274528B2 (en) 2010-07-09 2015-04-23 Genentech, Inc. Anti-neuropilin antibodies and methods of use
WO2012010582A1 (en) 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
DK3029066T3 (da) 2010-07-29 2019-05-20 Xencor Inc Antistoffer med modificerede isoelektriske punkter
TW201206473A (en) 2010-08-03 2012-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2012018771A1 (en) 2010-08-03 2012-02-09 Genentech, Inc. Chronic lymphocytic leukemia (cll) biomarkers
BR112013002532A2 (pt) 2010-08-05 2016-05-31 Hoffmann La Roche proteína de fusão de citocina anti-viral do anticorpo anti-mhc
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
NO2603530T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2010-08-13 2018-04-07
BR112013002444A2 (pt) 2010-08-13 2016-05-24 Roche Glycart Ag anticorpo, polinucleotídeo e polipeotídeo isolados, composição, vetor, cécula hospedeira, conjulgado de anticorpo, formulação farmacêutica, uso do anticorpo, métodos para produzir um anticorpo, tratar um indivíduo, induzir a lise celular de uma célula tumorosa e diagnosticar uma doença em um indivíduo
TW201208703A (en) 2010-08-17 2012-03-01 Roche Glycart Ag Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
MX340555B (es) 2010-08-25 2016-07-14 F Hoffmann-La Roche Ag * Anticuerpos contra il-18r1 y usos de los mismos.
KR20130139884A (ko) 2010-08-26 2013-12-23 애브비 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
BR112013004673A8 (pt) 2010-08-31 2018-01-02 Genentech Inc biomarcadores e métodos de tratamento.
RS63430B1 (sr) 2010-10-01 2022-08-31 Modernatx Inc Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene
AU2011312205B2 (en) 2010-10-05 2015-08-13 Curis, Inc. Mutant smoothened and methods of using the same
CN103476793A (zh) 2010-11-08 2013-12-25 基因技术公司 皮下施用的抗-il-6受体抗体
PH12013500933A1 (en) 2010-11-10 2017-08-23 Genentech Inc Methods and compositions for neural disease immunotherapy
BR122020012255B1 (pt) 2010-12-16 2022-08-09 Genentech, Inc Uso de um anticorpo anti-il-13, usos de um inibidor da via de th2 e anticorpos anti-periostina
BR112013014522A2 (pt) 2010-12-16 2017-09-26 Roche Glycart Ag anticorpo anti-cd20 afucosilado e seu uso, composição e método para tratamento de um paciente que sofre de câncer
PH12013501323A1 (en) 2010-12-20 2013-08-28 Genentech Inc Anti-mesothelin antibodies and immunoconjugates
AU2011348232A1 (en) 2010-12-22 2013-07-18 Genentech, Inc. Anti-PCSK9 antibodies and methods of use
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
EP2482074A1 (en) * 2011-01-27 2012-08-01 Medizinische Hochschule Hannover Methods and means for diagnosing vasculitis
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
BR112013019083A2 (pt) 2011-02-10 2017-04-04 Roche Glycart Ag combinação de (a) um imunoconjugado, composição farmacêutica, uso de (a) um imunoconjugado, método de tratamento de uma doença em um individuo, método de estímulo de função celular efetora em um indivíduo e kit destinado ao tratamento de uma doença.
CN103502472B (zh) 2011-02-28 2017-06-06 弗·哈夫曼-拉罗切有限公司 生物标记物和用于预测对b‑细胞拮抗剂的响应的方法
CA2825081A1 (en) 2011-02-28 2012-09-07 Birgit Bossenmaier Antigen binding proteins
EP2681240B1 (en) 2011-02-28 2017-08-16 F. Hoffmann-La Roche AG Monovalent antigen binding proteins
US20120222851A1 (en) * 2011-03-04 2012-09-06 GM Global Technology Operations LLC Hvac system damper
PL2691417T5 (pl) 2011-03-29 2025-02-10 Roche Glycart Ag Warianty fc przeciwciała
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EP2694551A1 (en) 2011-04-07 2014-02-12 Genentech, Inc. Anti-fgfr4 antibodies and methods of use
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
WO2012146630A1 (en) 2011-04-29 2012-11-01 F. Hoffmann-La Roche Ag N-terminal acylated polypeptides, methods for their production and uses thereof
CA2833212C (en) 2011-05-12 2020-06-09 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
EP3219730A1 (en) 2011-05-16 2017-09-20 F. Hoffmann-La Roche AG Fgfr1 agonists and methods of use
EP3492494A1 (en) 2011-05-21 2019-06-05 MacroGenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
RU2013158627A (ru) 2011-06-15 2015-07-20 Ф. Хоффманн-Ля Рош Аг Антитела к рецептору человеческого эритропоэтина и способы их применения
CN103635487B (zh) 2011-06-17 2016-10-12 诺沃—诺迪斯克有限公司 选择性消除侵蚀性细胞
PH12013502499A1 (en) 2011-06-22 2019-03-22 Hoffmann La Roche Removal of target cells by circulating virus-specific cytotoxic t-cells using mhc class i comprising complexes
KR20140045440A (ko) 2011-06-30 2014-04-16 제넨테크, 인크. 항-c-met 항체 제제
KR20140057326A (ko) 2011-08-17 2014-05-12 제넨테크, 인크. 뉴레귤린 항체 및 그의 용도
WO2013025944A1 (en) 2011-08-17 2013-02-21 Genentech, Inc. Inhibition of angiogenesis in refractory tumors
CN103890006A (zh) 2011-08-23 2014-06-25 罗切格利卡特公司 抗mcsp抗体
CA2844538C (en) 2011-08-23 2020-09-22 Roche Glycart Ag Bispecific antigen binding molecules
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2014109395A (ru) 2011-09-15 2015-10-20 Дженентек, Инк. Способы стимуляции дифференциации
MX2014002990A (es) 2011-09-19 2014-05-21 Genentech Inc Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf.
KR20190099538A (ko) 2011-10-03 2019-08-27 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
US20130089562A1 (en) 2011-10-05 2013-04-11 Genenthech, Inc. Methods of treating liver conditions using notch2 antagonists
BR112014008862A2 (pt) 2011-10-14 2018-08-07 Genentech Inc anticorpo isolado que se liga à htra1, ácido nucleico isolado, célula hospedeira, imunoconjugado, formulação farmacêutica, métodos e usos
WO2013056148A2 (en) 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
WO2013059531A1 (en) 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
CN107233569B (zh) 2011-10-25 2021-08-31 普罗西纳生物科学有限公司 抗体制剂和方法
MX2014004991A (es) 2011-10-28 2014-05-22 Genentech Inc Combinaciones terapeuticas y metodos para tratar el melanoma.
KR102057742B1 (ko) * 2011-11-17 2019-12-19 군드람 정 의학적 용도를 위한 이중특이성 항체
BR112014012005A2 (pt) 2011-11-21 2017-12-19 Genentech Inc composições, métodos, formulação farmacêutica e artigo
US20130302274A1 (en) 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
WO2013083497A1 (en) 2011-12-06 2013-06-13 F. Hoffmann-La Roche Ag Antibody formulation
RU2685867C2 (ru) 2011-12-15 2019-04-23 Алтернатив Инновейтив Текнолоджиз Ллц Гибридные белки и белковые конъюгаты на основе белка теплового шока-70 (БТШ70) и способы их применения (варианты)
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
US9963511B2 (en) 2011-12-22 2018-05-08 Hoffmann-La Roche Inc. Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
TR201815709T4 (tr) 2011-12-22 2018-11-21 Hoffmann La Roche İyon değişim membranı kromatografisi.
MX2014007262A (es) 2011-12-22 2014-08-01 Hoffmann La Roche Sistema de exhibicion de anticuerpos de longitud completa para celulas eucarioticas y su uso.
SG10201900915WA (en) 2011-12-22 2019-03-28 Hoffmann La Roche Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
AR089434A1 (es) 2011-12-23 2014-08-20 Genentech Inc Procedimiento para preparar formulaciones con alta concentracion de proteinas
PL3130347T3 (pl) 2011-12-30 2020-04-30 Halozyme, Inc. Warianty polipeptydu ph20, ich formulacje i zastosowania
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
EP2797955A2 (en) 2011-12-30 2014-11-05 AbbVie Inc. Dual variable domain immunoglobulins against il-13 and/or il-17
CA2863224A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
EP2802601B1 (en) 2012-01-09 2019-11-13 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
AR089752A1 (es) 2012-01-18 2014-09-17 Genentech Inc Anticuerpos anti-lrp5 y metodos de uso
WO2013109856A2 (en) 2012-01-18 2013-07-25 Genentech, Inc. Methods of using fgf19 modulators
EP2804952A4 (en) * 2012-01-19 2015-09-09 Therapeutic Proteins Int Llc STABILIZATION OF ANTI-CD20 ANTIBODY RITUXIMAB
US20130243750A1 (en) 2012-01-31 2013-09-19 Genentech, Inc. Anti-ige antibodies and methods using same
EP2812350B1 (en) 2012-02-11 2019-04-03 F.Hoffmann-La Roche Ag R-spondin translocations and methods using the same
CA3159061A1 (en) 2012-02-15 2013-08-22 F. Hoffmann-La Roche Ag Fc-receptor based affinity chromatography
CA2865082A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
CA2866753C (en) 2012-03-27 2020-09-22 Genentech, Inc. Improved harvest operations for recombinant proteins
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
WO2013151670A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
KR102132041B1 (ko) 2012-04-05 2020-07-09 에이씨 이뮨 에스.에이. 인간화된 타우 항체
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
AR090903A1 (es) 2012-05-01 2014-12-17 Genentech Inc Anticuerpos e inmunoconjugados anti-pmel17
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
CN104335047B (zh) 2012-05-23 2017-08-15 弗·哈夫曼-拉罗切有限公司 治疗剂的选择方法
KR20150023711A (ko) 2012-06-15 2015-03-05 제넨테크, 인크. 항-pcsk9 항체, 제제, 투여, 및 사용 방법
JP6247287B2 (ja) 2012-07-04 2017-12-13 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ビオチン抗体および使用方法
CA2872184A1 (en) 2012-07-04 2014-01-09 F. Hoffmann-La Roche Ag Anti-theophylline antibodies and methods of use
EA028750B1 (ru) 2012-07-04 2017-12-29 Ризен Фармасьютикалз Са Селективные ингибиторы pi3k дельта
NZ701040A (en) 2012-07-04 2017-02-24 Hoffmann La Roche Covalently linked antigen-antibody conjugates
JP6309518B2 (ja) 2012-07-05 2018-04-11 ジェネンテック， インコーポレイテッド 発現及び分泌システム
MX2015000315A (es) 2012-07-09 2015-07-06 Genentech Inc Anticuerpos anti-cd22 e inmunoconjugados.
CA2873889A1 (en) 2012-07-09 2014-01-16 Genentech, Inc. Anti-cd22 antibodies and immunoconjugates
SG11201500093TA (en) 2012-07-09 2015-02-27 Genentech Inc Immunoconjugates comprising anti-cd79b antibodies
EP2869847B1 (en) 2012-07-09 2017-12-06 Genentech, Inc. Immunoconjugates comprising anti-cd79b antibodies
US9670276B2 (en) 2012-07-12 2017-06-06 Abbvie Inc. IL-1 binding proteins
LT3495387T (lt) 2012-07-13 2021-11-25 Roche Glycart Ag Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
JP6307077B2 (ja) 2012-08-02 2018-04-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 不活性免疫グロブリンＦｃ領域とのＦｃ融合体としての可溶性ＦｃＲを生産するための方法およびその使用
EP2882777B1 (en) 2012-08-07 2018-10-10 Roche Glycart AG Composition comprising two antibodies engineered to have reduced and increased effector function
JP6302909B2 (ja) 2012-08-18 2018-03-28 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ シアリダーゼの同定および画像化のための細胞透過性プローブ
US9547009B2 (en) 2012-08-21 2017-01-17 Academia Sinica Benzocyclooctyne compounds and uses thereof
WO2014052713A2 (en) 2012-09-27 2014-04-03 Massachusetts Institute Of Technology Her2-and vegf-a-binding proteins with enhanced stability
AU2013337775B2 (en) 2012-11-01 2017-03-30 Abbvie Inc. Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
CN105073197B (zh) 2012-11-02 2019-06-28 Tg疗法有限公司 抗cd20抗体和pi3激酶选择性抑制剂的组合
EP2914621B1 (en) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
CA2890346A1 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
MX2015005757A (es) 2012-11-08 2015-11-18 Hoffmann La Roche Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3.
CA2890669A1 (en) 2012-11-13 2014-05-22 Genetech, Inc. Anti-hemagglutinin antibodies and methods of use
JP6475631B2 (ja) 2012-11-19 2019-02-27 バリオファルム・アクチェンゲゼルシャフト Ｃｄ２０およびｃｄ９５に結合する組換え二重特異性抗体
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
EP2934602B1 (en) 2012-12-19 2019-02-27 Genentech, Inc. Methods and compositions for radiohalogen protein labeling
PL2935328T3 (pl) 2012-12-21 2019-02-28 Hoffmann La Roche Połączone wiązaniem dwusiarczkowym wielowartościowe białka wielofunkcyjne zawierające MHC klasy I
WO2014113729A2 (en) 2013-01-18 2014-07-24 Foundation Mecicine, Inc. Methods of treating cholangiocarcinoma
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
WO2014120555A1 (en) 2013-01-31 2014-08-07 The Regents Of The University Of California Antibodies specific for urokinase-type plasminogen activator and methods of use thereof
EP2958592A1 (en) 2013-02-22 2015-12-30 F. Hoffmann-La Roche AG Methods of treating cancer and preventing drug resistance
HK1211301A1 (en) 2013-02-26 2016-05-20 罗切格利卡特公司 Anti-mcsp antibodies
JP2016510751A (ja) 2013-03-06 2016-04-11 ジェネンテック， インコーポレイテッド 抗がん剤耐性を治療及び予防する方法
RS60280B1 (sr) 2013-03-12 2020-06-30 Molecular Templates Inc Citotoksični proteini koji sadrže ciljane vezujuće regione za ćelije i regioni shiga toksina a podjedinice za selektivno ubijanje određenih vrsta ćelija
EP2968553B1 (en) 2013-03-13 2020-08-12 F.Hoffmann-La Roche Ag Antibody formulations
CA2902865A1 (en) 2013-03-14 2014-10-02 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
CN105246508A (zh) 2013-03-14 2016-01-13 基因泰克公司 Mek抑制剂化合物与her3/egfr抑制剂化合物的组合及使用方法
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
MX2015011606A (es) 2013-03-14 2016-05-17 Genentech Inc Metodo para tratar cancer y prevenir resistencia a farmacos contra cancer.
CN118547067A (zh) 2013-03-15 2024-08-27 豪夫迈·罗氏有限公司 治疗pd-1和pd-l1相关疾患的生物标志物和方法
TW201522374A (zh) 2013-03-15 2015-06-16 Genentech Inc 抗ｃｒｔｈ２抗體及使用方法
BR112015021993A8 (pt) * 2013-03-15 2019-12-03 Genentech Inc polipeptídeo, métodos para sua produção, métodos para cultivo de uma célula, composição farmacêutica, kit, e meio de cultura celular
EP2970459A2 (en) 2013-03-15 2016-01-20 AbbVie Inc. Dual specific binding proteins directed against il-1beta and il-17
RU2661111C2 (ru) 2013-03-15 2018-07-11 Ац Иммуне С.А. Антитела к тау и способы применения
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
MX2015011444A (es) 2013-03-15 2015-12-16 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento del cancer hepatico.
JP2016520528A (ja) 2013-03-15 2016-07-14 ジェネンテック， インコーポレイテッド 癌の治療及び抗癌剤耐性の防止方法
UA118843C2 (uk) 2013-03-15 2019-03-25 Дженентек, Інк. ХИМЕРНИЙ БІЛОК IL-22 Fc ТА ЙОГО ЗАСТОСУВАННЯ
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
TWI747803B (zh) 2013-04-29 2021-12-01 瑞士商赫孚孟拉羅股份公司 人類結合ｆｃｒｎ之經修飾抗體及使用方法
MX2015015060A (es) 2013-04-29 2016-02-25 Hoffmann La Roche Anticuerpos asimetricos modificados que se unen al receptor fc y metodos de uso.
SG11201508910WA (en) 2013-04-29 2015-11-27 Hoffmann La Roche Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
JP6612214B2 (ja) 2013-05-20 2019-11-27 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及び使用方法
BR112015029838A2 (pt) 2013-05-31 2017-09-26 Genentech Inc anticorpos, composições, ácido nucleico isolado, vetor, célula hospedeira isolada, método de produção de anticorpos, composto, conjugado de anticorpo e antibiótico, processo de elaboração do composto, intermediário entre ligante e antibiótico, método de tratamento de infecções bacterianas e método de matar staphylococcus aureus
RU2687044C2 (ru) 2013-05-31 2019-05-06 Дженентек, Инк. Антитела против стеночной тейхоевой кислоты и их конъюгаты
WO2014210397A1 (en) 2013-06-26 2014-12-31 Academia Sinica Rm2 antigens and use thereof
EP3013347B1 (en) 2013-06-27 2019-12-11 Academia Sinica Glycan conjugates and use thereof
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
CN105814074B (zh) 2013-07-18 2020-04-21 图鲁斯生物科学有限责任公司 具有超长互补决定区的人源化抗体
EP3022224A2 (en) 2013-07-18 2016-05-25 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
NZ715201A (en) 2013-08-01 2021-12-24 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
WO2015023596A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. Compositions and method for treating complement-associated conditions
WO2015035337A1 (en) 2013-09-06 2015-03-12 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS
JP2016537399A (ja) 2013-09-17 2016-12-01 ジェネンテック， インコーポレイテッド 抗ｌｇｒ５抗体を使用する方法
CN103524621B (zh) * 2013-09-27 2015-04-01 北京济福霖生物技术有限公司 一种抗人cd20嵌合单克隆抗体
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
CN105980401A (zh) 2013-10-03 2016-09-28 现代治疗公司 编码低密度脂蛋白受体的多核苷酸
EP3055329B1 (en) 2013-10-11 2018-06-13 F. Hoffmann-La Roche AG Multispecific domain exchanged common variable light chain antibodies
AU2014331667B2 (en) 2013-10-11 2019-08-22 Biomed Valley Discoveries, Inc. TEM8 antibodies and their use
EP3055328A1 (en) 2013-10-11 2016-08-17 F. Hoffmann-La Roche AG Nsp4 inhibitors and methods of use
RU2016114074A (ru) 2013-10-18 2017-11-23 Дженентек, Инк. Анти-rspo антитела и способы применения
SG11201603127WA (en) 2013-10-23 2016-05-30 Genentech Inc Methods of diagnosing and treating eosinophilic disorders
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
NZ717673A (en) 2013-11-21 2020-02-28 Hoffmann La Roche Anti-alpha-synuclein antibodies and methods of use
EP3079719B8 (en) 2013-12-09 2019-12-04 Allakos Inc. Anti-siglec-8 antibodies and methods of use thereof
EP3461845B1 (en) 2013-12-13 2020-09-16 Genentech, Inc. Anti-cd33 antibodies and immunoconjugates
AU2014364606A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
SG10202002334PA (en) 2013-12-17 2020-05-28 Genentech Inc Methods of treating cancers using pd-1 axis binding antagonists and taxanes
EP3083690A1 (en) 2013-12-17 2016-10-26 F.Hoffmann-La Roche Ag Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
CA3055708C (en) 2013-12-17 2023-01-31 Xiaocheng Chen Anti-cd3 antibodies and methods of use
SI3083680T1 (sl) 2013-12-20 2020-06-30 F. Hoffmann-La Roche Ag Humanizirana protitelesa proti beljakovini Tau(pS422) in postopki uporabe
TWI670283B (zh) 2013-12-23 2019-09-01 美商建南德克公司 抗體及使用方法
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
CA2930154A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
CN105873616B (zh) 2014-01-03 2020-06-05 豪夫迈·罗氏有限公司 共价连接的多肽毒素-抗体缀合物
MX373097B (es) 2014-01-03 2020-04-27 Hoffmann La Roche Anticuerpos biespecíficos anti-hapteno/anti-receptor de barrera hematoencefálica, complejos de los mismos y su uso como transportadores a través de la barrera hematoencefálica.
WO2015101588A1 (en) 2014-01-06 2015-07-09 F. Hoffmann-La Roche Ag Monovalent blood brain barrier shuttle modules
JP6786392B2 (ja) 2014-01-15 2020-11-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＦｃＲｎ結合特性が改変され、プロテインＡ結合特性が保持されているＦｃ領域変異体
US9982041B2 (en) 2014-01-16 2018-05-29 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
EP3096797A1 (en) 2014-01-24 2016-11-30 F. Hoffmann-La Roche AG Methods of using anti-steap1 antibodies and immunoconjugates
IL294746B2 (en) 2014-01-27 2024-04-01 Molecular Templates Inc SHIGA toxin-free effector subunit-containing polypeptides for mammalian applications
WO2015120075A2 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
KR20160111039A (ko) 2014-02-08 2016-09-23 제넨테크, 인크. 알츠하이머 질환을 치료하는 방법
EP3900738A1 (en) 2014-02-08 2021-10-27 F. Hoffmann-La Roche AG Methods of treating alzheimer's disease
PE20161335A1 (es) 2014-02-12 2016-12-07 Genentech Inc Anticuerpos anti-jagged1 y metodos de uso
CN106029693A (zh) 2014-02-21 2016-10-12 豪夫迈·罗氏有限公司 抗il-13/il-17双特异性抗体及其用途
TWI558399B (zh) 2014-02-26 2016-11-21 美國禮來大藥廠 癌症之組合療法
EP3110446B1 (en) 2014-02-28 2021-12-01 Allakos Inc. Methods and compositions for treating siglec-8 associated diseases
TW201622744A (zh) 2014-03-04 2016-07-01 美國禮來大藥廠 癌症之組合療法
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
EP3116999B1 (en) 2014-03-14 2021-09-15 F. Hoffmann-La Roche AG Methods and compositions for secretion of heterologous polypeptides
WO2015140591A1 (en) 2014-03-21 2015-09-24 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
MX2016012285A (es) 2014-03-24 2017-01-23 Genentech Inc Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
WO2015148915A1 (en) 2014-03-27 2015-10-01 Academia Sinica Reactive labelling compounds and uses thereof
HUE046767T2 (hu) 2014-03-31 2020-03-30 Hoffmann La Roche Anti-OX40 antitestek és alkalmazási eljárások
MA39817A (fr) 2014-03-31 2017-02-08 Hoffmann La Roche Thérapie combinatoires comprenant des agents anti-angiogenèse et des agonistes se liant à ox40
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
JP2017522861A (ja) 2014-05-22 2017-08-17 ジェネンテック， インコーポレイテッド 抗ｇｐｃ３抗体及びイムノコンジュゲート
MX2016015163A (es) 2014-05-23 2017-03-03 Genentech Inc Biomarcadores mit y metodos para su uso.
JP2017518989A (ja) 2014-05-27 2017-07-13 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 抗ｃｄ２０糖操作抗体群およびその使用
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
EP3149161B1 (en) 2014-05-27 2021-07-28 Academia Sinica Fucosidase from bacteroides and methods using the same
JP7062361B2 (ja) 2014-05-27 2022-05-06 アカデミア シニカ 抗ｈｅｒ２糖操作抗体群およびその使用
KR20170007480A (ko) 2014-05-27 2017-01-18 리젠 파마슈티컬스 소시에떼 아노님 약제학적 제형에 사용하기 위한 pi3k 델타 선택적 억제제의 개선된 형태
KR102494193B1 (ko) 2014-05-28 2023-01-31 아카데미아 시니카 항-ｔｎｆ-알파 글리코항체 및 이의 용도
ES2919749T3 (es) 2014-06-11 2022-07-28 Molecular Templates Inc Moléculas dirigidas a células citotóxicas resistentes a la escisión por proteasa
EP3155015A1 (en) 2014-06-11 2017-04-19 F. Hoffmann-La Roche AG Anti-lgr5 antibodies and uses thereof
CN107073121A (zh) 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
CN106687476B (zh) 2014-06-26 2020-11-13 豪夫迈·罗氏有限公司 抗brdu抗体及使用方法
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
JP2017526641A (ja) 2014-07-11 2017-09-14 ジェネンテック， インコーポレイテッド Ｎｏｔｃｈ経路阻害
DK3309174T3 (da) 2014-07-11 2022-06-07 Ventana Med Syst Inc ANTI-PD-L1-antistoffer og diagnostiske anvendelser deraf
WO2016019969A1 (en) 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
MX2017002605A (es) 2014-08-28 2017-05-19 Bioatla Llc Receptores de antigeno quimerico condicionalmente activos para celulas t modificadas.
US20170246272A1 (en) 2014-09-05 2017-08-31 Opexa Therapeutics, Inc. Compositions and methods for treating b cell mediated autoimmune disorders
KR102422375B1 (ko) 2014-09-08 2022-07-18 아카데미아 시니카 당지질을 사용한 인간 iNKT 세포 활성화
AR101848A1 (es) 2014-09-12 2017-01-18 Genentech Inc Anticuerpos de anti-b7-h4 e inmunoconjugados
CR20170131A (es) 2014-09-12 2017-07-19 Genentech Inc Anticuerpos anti-her2 e inmunoconjugados
WO2016040868A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anti-cll-1 antibodies and immunoconjugates
CN107108724A (zh) 2014-09-12 2017-08-29 豪夫迈·罗氏有限公司 半胱氨酸改造抗体和缀合物
AU2015318001B2 (en) 2014-09-15 2021-03-25 Genentech, Inc. Antibody formulations
JP6730261B2 (ja) 2014-09-17 2020-07-29 ジェネンテック， インコーポレイテッド 抗ｈｅｒ２抗体を含む免疫複合体
ES2796903T3 (es) 2014-09-23 2020-11-30 Hoffmann La Roche Procedimiento de uso de inmunoconjugados anti-CD79b
JP2017536102A (ja) 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
WO2016070001A1 (en) 2014-10-31 2016-05-06 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind b7-h4
BR112017009151A2 (pt) 2014-11-03 2018-03-06 Genentech, Inc. ensaios para detectar subgrupos imunológicos de célula t e métodos de uso dos mesmos
BR112017009159A2 (pt) 2014-11-03 2018-03-06 Genentech, Inc. métodos e biomarcadores para predizer a eficácia e avaliação de um tratamento com agonista de ox40
WO2016073791A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Methods of producing two chain proteins in bacteria
WO2016073789A2 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
ES2819256T3 (es) 2014-11-05 2021-04-15 Genentech Inc Métodos para producir proteínas bicatenarias en bacterias
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
EP3842453A1 (en) 2014-11-06 2021-06-30 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn- and protein a-binding properties
KR20170078677A (ko) 2014-11-06 2017-07-07 에프. 호프만-라 로슈 아게 Fcrn-결합이 개질된 fc-영역 변이체 및 이의 사용 방법
WO2016073282A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Combination therapy comprising ox40 binding agonists and tigit inhibitors
CN107105632A (zh) 2014-11-10 2017-08-29 豪夫迈·罗氏有限公司 肾病动物模型及其治疗剂
EP3218403B1 (en) 2014-11-10 2020-05-13 F.Hoffmann-La Roche Ag Anti-interleukin-33 antibodies and uses thereof
EP3875481B1 (en) 2014-11-14 2025-01-22 The U.S.A. as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
KR20170096112A (ko) 2014-11-17 2017-08-23 제넨테크, 인크. Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
JP6779876B2 (ja) 2014-11-19 2020-11-04 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用方法
JP6993228B2 (ja) 2014-11-19 2022-03-03 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
US10882920B2 (en) 2014-11-19 2021-01-05 Genentech, Inc. Antibodies against BACE1 and use thereof for neural disease immunotherapy
HRP20240959T1 (hr) 2014-11-20 2024-10-25 F. Hoffmann - La Roche Ag Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t stanice i antagonistom vezivanja osi pd-1
WO2016090040A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
RU2731055C2 (ru) 2014-12-03 2020-08-28 Дженентек, Инк. Конъюгаты антитела к staphylococcus aureus с рифамицином и их применение
ES2764111T3 (es) 2014-12-03 2020-06-02 Hoffmann La Roche Anticuerpos multiespecíficos
US9975949B2 (en) 2014-12-05 2018-05-22 Genentech, Inc. Anti-CD79b antibodies and methods of use
EP3230317A2 (en) 2014-12-10 2017-10-18 F. Hoffmann-La Roche AG Blood brain barrier receptor antibodies and methods of use
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
LT3233921T (lt) 2014-12-19 2021-12-10 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antikūnai ir panaudojimo būdai
AR103161A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
CN107278206B (zh) 2014-12-19 2021-04-02 雷根尼桑斯公司 结合人c6的抗体及其用途
WO2016111947A2 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
AU2016206457B2 (en) 2015-01-16 2021-11-11 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ROR1
US20180016327A1 (en) 2015-01-22 2018-01-18 Chugai Seiyaku Kabushiki Kaisha A Combination of Two or More Anti-C5 Antibodies and Methods of Use
US10342858B2 (en) 2015-01-24 2019-07-09 Academia Sinica Glycan conjugates and methods of use thereof
EP3250604B1 (en) * 2015-01-26 2021-04-21 Cellectis Mab-driven chimeric antigen receptor systems for sorting/depleting engineered immune cells
AU2016215227A1 (en) 2015-02-04 2017-09-21 Assistance Publique-Hopitaux De Paris Mutant smoothened and methods of using the same
KR20170110601A (ko) 2015-02-05 2017-10-11 몰레큘러 템플레이츠, 인코퍼레이션. 시가 독소 a 서브유닛 작동체 영역을 포함하는 다가 cd20 결합 분자 및 이들의 강화된 조성물
TWI844507B (zh) 2015-02-05 2024-06-11 日商中外製藥股份有限公司 包含離子濃度依賴之抗原結合域的抗體、Ｆｃ區變體與其用途
KR20170140180A (ko) 2015-02-24 2017-12-20 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 중동 호흡기 증후군 코로나 바이러스 면역원, 항체 및 그 용도
EP3271723A1 (en) 2015-03-16 2018-01-24 F. Hoffmann-La Roche AG Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
EP3683233A1 (en) 2015-03-20 2020-07-22 The U.S.A. as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to gp120 and their use
MX386500B (es) 2015-03-23 2025-03-19 Jounce Therapeutics Inc Anticuerpos contra icos
PE20171790A1 (es) 2015-03-23 2017-12-28 Bayer Pharma AG Anticuerpos anti-ceacam6 y sus usos
US10472412B2 (en) 2015-03-25 2019-11-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bispecific multivalent fusion proteins
HK1249048A1 (zh) 2015-04-03 2018-10-26 Eureka Therapeutics, Inc. 靶向afp肽/mhc複合體的構建體及其用途
WO2016164480A1 (en) 2015-04-07 2016-10-13 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use
PT3283508T (pt) 2015-04-17 2021-06-21 Alpine Immune Sciences Inc Proteínas imuno modulatórias com afinidades afináveis
WO2016172551A2 (en) 2015-04-24 2016-10-27 Genentech, Inc. Methods of identifying bacteria comprising binding polypeptides
EP3288981A1 (en) 2015-05-01 2018-03-07 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
WO2016179194A1 (en) 2015-05-04 2016-11-10 Jounce Therapeutics, Inc. Lilra3 and method of using the same
JP6963508B2 (ja) 2015-05-11 2021-11-10 ジェネンテック， インコーポレイテッド ループス腎炎を治療する組成物及び方法
EP3294770B2 (en) 2015-05-12 2024-03-20 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for cancer
AU2016263808B2 (en) 2015-05-21 2019-01-03 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
EP3302563A1 (en) 2015-05-29 2018-04-11 H. Hoffnabb-La Roche Ag Humanized anti-ebola virus glycoprotein antibodies and methods of use
PL3303619T3 (pl) 2015-05-29 2020-10-05 F. Hoffmann-La Roche Ag Metylacja promotora PD-L1 w chorobach nowotworowych
CN107532217A (zh) 2015-05-29 2018-01-02 豪夫迈·罗氏有限公司 用于癌症的治疗和诊断方法
US20180258143A1 (en) 2015-05-30 2018-09-13 Molecular Templates, Inc. De-Immunized, Shiga Toxin A Subunit Scaffolds and Cell-Targeting Molecules Comprising the Same
HK1249016A1 (zh) 2015-06-02 2018-10-26 豪夫迈‧罗氏有限公司 使用抗il-34抗体治疗神经疾病的组合物和方法
WO2016196975A1 (en) 2015-06-03 2016-12-08 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Neutralizing antibodies to hiv-1 env and their use
EP4465050A3 (en) 2015-06-05 2025-06-11 Genentech, Inc. Anti-tau antibodies and methods of use
MX2017015937A (es) 2015-06-08 2018-12-11 Genentech Inc Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1.
MX2017014740A (es) 2015-06-08 2018-08-15 Genentech Inc Métodos de tratamiento del cáncer con anticuerpos anti-ox40.
JP2018524295A (ja) 2015-06-15 2018-08-30 ジェネンテック， インコーポレイテッド 抗体及び免疫複合体
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
JP6871874B2 (ja) 2015-06-16 2021-05-19 ジェネンテック， インコーポレイテッド ＦｃＲＨ５に対するヒト化親和性成熟抗体及び使用方法
EP3916018A1 (en) 2015-06-16 2021-12-01 Genentech, Inc. Anti-cd3 antibodies and methods of use
WO2016205200A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Anti-cll-1 antibodies and methods of use
CA2987797A1 (en) 2015-06-17 2016-12-22 Christopher Robert Bebbington Methods and compositions for treating fibrotic diseases
IL256080B2 (en) 2015-06-17 2025-06-01 Genentech Inc Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
JP2018524312A (ja) 2015-06-17 2018-08-30 ジェネンテック， インコーポレイテッド 抗ｈｅｒ２抗体及び使用方法
EP3313890A1 (en) 2015-06-24 2018-05-02 H. Hoffnabb-La Roche Ag Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
SI3313879T1 (sl) 2015-06-24 2022-04-29 F. Hoffmann-La Roche Ag Protitelesa z antitransferinskim receptorjem s prilagojeno afiniteto
CN113929779B (zh) 2015-06-24 2025-02-25 豪夫迈·罗氏有限公司 人源化的抗-Tau(pS422)抗体和使用方法
EP3108897A1 (en) 2015-06-24 2016-12-28 F. Hoffmann-La Roche AG Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
CA2989936A1 (en) 2015-06-29 2017-01-05 Genentech, Inc. Type ii anti-cd20 antibody for use in organ transplantation
ES2878316T3 (es) 2015-06-29 2021-11-18 Ventana Med Syst Inc Materiales y procedimientos para realizar ensayos histoquímicos de pro-epirregulina y anfirregulina humanas
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
WO2017040342A1 (en) 2015-08-28 2017-03-09 Genentech, Inc. Anti-hypusine antibodies and uses thereof
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
MY203894A (en) 2015-09-18 2024-07-23 Chugai Pharmaceutical Co Ltd Il-8-binding antibodies and uses thereof
JP6904947B2 (ja) 2015-09-22 2021-07-21 スプリング バイオサイエンス コーポレーション 抗ｏｘ４０抗体及びその診断用途
PE20181363A1 (es) 2015-09-23 2018-08-27 Genentech Inc Variantes optimizadas de anticuerpos anti-vegf
WO2017053906A1 (en) 2015-09-24 2017-03-30 Abvitro Llc Hiv antibody compositions and methods of use
EP3353210B8 (en) 2015-09-25 2024-12-18 F. Hoffmann-La Roche AG Anti-tigit antibodies and methods of use
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
SI3356411T1 (sl) 2015-10-02 2021-09-30 F. Hoffmann-La Roche Ag Bispecifična protitelesa, specifična za PD1 in TIM3
CN108137697A (zh) 2015-10-02 2018-06-08 豪夫迈·罗氏有限公司 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MX388018B (es) 2015-10-02 2025-03-19 Hoffmann La Roche Anticuerpos anti-pd1 y métodos de uso.
JP7034066B2 (ja) 2015-10-02 2022-03-11 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 共刺激ｔｎｆ受容体に対する二重特異性抗体
EP3150636A1 (en) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
LT3359572T (lt) 2015-10-06 2025-02-10 F. Hoffmann-La Roche Ag Išsėtinės sklerozės gydymo būdas
EP3359568B1 (en) 2015-10-07 2022-03-09 F. Hoffmann-La Roche AG Bispecific antibodies with tetravalency for a costimulatory tnf receptor
CA2997809A1 (en) 2015-10-07 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
JP2018534927A (ja) 2015-10-22 2018-11-29 ジョンス セラピューティクス， インコーポレイテッド Ｉｃｏｓ発現を決定する遺伝子シグネチャー
IL295756A (en) 2015-10-29 2022-10-01 Hoffmann La Roche Anti-variant fc-region antibodies and methods of use
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
PH12022550450A1 (en) 2015-10-30 2023-05-03 Genentech Inc Anti-htra1 antibodies and methods of use thereof
EP4011911A1 (en) 2015-11-03 2022-06-15 The United States of America as represented by The Secretary Department of Health and Human Services Neutralizing antibodies to hiv-1 gp41 and their use
WO2017079768A1 (en) 2015-11-08 2017-05-11 Genentech, Inc. Methods of screening for multispecific antibodies
BR112018010410A8 (pt) 2015-11-23 2019-02-26 Five Prime Therapeutics Inc método para tratar câncer em um sujeito, composição e métodos de aumento do número de células nk e de aumento do número de uma ou mais células positivas para pd-l1
IL257696B2 (en) 2015-12-09 2024-11-01 Hoffmann La Roche Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
EP3178848A1 (en) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
EA201891420A1 (ru) 2015-12-18 2019-02-28 Чугаи Сейяку Кабусики Кайся Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
EA036756B1 (ru) 2015-12-18 2020-12-16 Чугаи Сейяку Кабусики Кайся Антитела к с5 и способы их применения
AU2016380988B2 (en) 2015-12-30 2022-07-21 Genentech, Inc. Formulations with reduced degradation of polysorbate
AR107303A1 (es) 2016-01-08 2018-04-18 Hoffmann La Roche Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
CN114019170A (zh) 2016-01-20 2022-02-08 基因泰克公司 用于阿尔茨海默氏病的高剂量治疗
WO2017136558A1 (en) 2016-02-04 2017-08-10 Curis, Inc. Mutant smoothened and methods of using the same
CA3015528A1 (en) 2016-02-29 2017-09-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
EP3423490A1 (en) 2016-03-01 2019-01-09 H. Hoffnabb-La Roche Ag Obinutuzumab and rituximab variants having reduced adcp
CA3016170A1 (en) 2016-03-08 2017-09-14 Academia Sinica Methods for modular synthesis of n-glycans and arrays thereof
EP3430054B1 (en) 2016-03-15 2021-12-29 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
CN108700598A (zh) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 多路总抗体和抗体缀合的药物量化测定法
MX394122B (es) 2016-03-29 2025-03-24 Geltor Inc Expresión de proteínas en bacterias gram negativas en la que la relación del volumen periplasmático con respecto al volumen citoplasmático está entre 0.5:1 y 10:1
KR101796277B1 (ko) * 2016-04-12 2017-11-13 앱클론(주) 안정성이 개선된 ｈｅｒ２에 특이적으로 결합하는 항체
EP3865511A1 (en) 2016-04-14 2021-08-18 F. Hoffmann-La Roche AG Anti-rspo3 antibodies and methods of use
EP3442562B1 (en) 2016-04-15 2022-09-21 Evive Biotechnology (Shanghai) Ltd An il-22 dimer for use in treating necrotizing enterocolitis
KR20230051602A (ko) 2016-04-15 2023-04-18 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
JP2019515670A (ja) 2016-04-15 2019-06-13 ジェネンテック， インコーポレイテッド がんをモニタリングし治療するための方法
AU2017250296A1 (en) 2016-04-15 2018-11-01 Genentech, Inc. Methods for monitoring and treating cancer
MA43552A (fr) 2016-04-15 2018-11-07 Alpine Immune Sciences Inc Protéines immunomodulatrices à variants de cd80 et leurs utilisations
WO2017180842A1 (en) 2016-04-15 2017-10-19 Bioatla, Llc Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
WO2017191101A1 (en) 2016-05-02 2017-11-09 F. Hoffmann-La Roche Ag The contorsbody - a single chain target binder
WO2017192589A1 (en) 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to influenza ha and their use and identification
CN109071640B (zh) 2016-05-11 2022-10-18 豪夫迈·罗氏有限公司 经修饰抗生腱蛋白抗体及使用方法
KR20240148936A (ko) 2016-05-13 2024-10-11 바이오아트라, 인코퍼레이티드 항 ror2 항체, 항체 단편 및 이의 면역접합체와 이것들의 용도
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
AU2017268839A1 (en) 2016-05-27 2018-11-29 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat B-cell proliferative disorders
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
CN109476648B (zh) 2016-06-06 2022-09-13 豪夫迈·罗氏有限公司 司维司群抗体-药物缀合物和使用方法
CN109311969B (zh) 2016-06-17 2022-09-27 中外制药株式会社 抗-肌肉生长抑制因子抗体及使用方法
JP7133477B2 (ja) 2016-06-24 2022-09-08 ジェネンテック， インコーポレイテッド 抗ポリユビキチン多重特異性抗体
JP6983824B2 (ja) 2016-07-04 2021-12-17 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 新規抗体フォーマット
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
EP3491013A1 (en) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
JP2019525934A (ja) 2016-07-29 2019-09-12 イーライ リリー アンド カンパニー 癌の治療に使用するためのメレスチニブおよび抗ｐｄ−ｌ１または抗ｐｄ−１阻害剤を用いた組み合わせ治療
EP3492496A4 (en) 2016-07-29 2020-07-29 Chugai Seiyaku Kabushiki Kaisha BISPECIFIC ANTIBODIES PRESENTING AN INCREASED ALTERNATIVE FUNCTIONAL ACTIVITY OF COFACTOR FVIII
CA3031734A1 (en) 2016-07-29 2018-02-01 Juno Therapeutics, Inc. Anti-idiotypic antibodies against anti-cd19 antibodies
WO2018025982A1 (ja) 2016-08-05 2018-02-08 中外製薬株式会社 Ｉｌ－８関連疾患の治療用又は予防用組成物
EP3494139B1 (en) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
JP7250674B2 (ja) 2016-08-08 2023-04-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療及び診断方法
EP3496763A1 (en) 2016-08-11 2019-06-19 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
JP7213549B2 (ja) 2016-08-22 2023-01-27 シーエイチオー ファーマ インコーポレイテッド 抗体、結合性断片、および使用の方法
EP3507305A1 (en) 2016-09-02 2019-07-10 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
WO2018049083A1 (en) 2016-09-07 2018-03-15 The Regents Of The University Of California Antibodies to oxidation-specific epitopes
WO2018049263A1 (en) 2016-09-09 2018-03-15 Tg Therapeutics, Inc. Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
EP3515932B1 (en) 2016-09-19 2023-11-22 F. Hoffmann-La Roche AG Complement factor based affinity chromatography
FI3528838T3 (fi) 2016-09-23 2023-10-02 Hoffmann La Roche IL-13-antagonistien käyttöjä atooppisen ihottuman hoitamiseksi
US11072660B2 (en) 2016-10-03 2021-07-27 Juno Therapeutics, Inc. HPV-specific binding molecules
CN110139674B (zh) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 制备抗体药物缀合物的方法
KR102804118B1 (ko) 2016-10-06 2025-05-09 제넨테크, 인크. 암에 대한 치료 및 진단 방법
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
US11555076B2 (en) 2016-10-29 2023-01-17 Genentech, Inc. Anti-MIC antibodies and methods of use
EP3988569A1 (en) 2016-11-02 2022-04-27 Jounce Therapeutics, Inc. Antibodies to pd-1 and uses thereof
KR20230111264A (ko) * 2016-11-07 2023-07-25 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 라임병에 사용하기 위한 dna 항체 작제물
AU2017361081B2 (en) 2016-11-15 2024-12-19 Genentech, Inc. Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
WO2018093669A1 (en) 2016-11-16 2018-05-24 Eli Lilly And Company Combination therapy for cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
EP3468991A1 (en) 2016-11-21 2019-04-17 cureab GmbH Anti-gp73 antibodies and immunoconjugates
SG10201911351SA (en) 2016-12-07 2020-02-27 Genentech Inc Anti-tau antibodies and methods of use
EP3551645A1 (en) 2016-12-07 2019-10-16 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
WO2018106776A2 (en) 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
MX2019006331A (es) 2016-12-12 2019-07-12 Genentech Inc Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos.
ES2847973T3 (es) 2016-12-20 2021-08-04 Hoffmann La Roche Politerapia de anticuerpos biespecíficos anti-CD20/anti-CD3 y agonistas de 4-1BB (CD137)
JOP20190134A1 (ar) 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
AU2018206138A1 (en) 2017-01-03 2019-07-11 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising anti-4-1BB clone 20H4.9
WO2018129029A1 (en) 2017-01-04 2018-07-12 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
TW201831517A (zh) 2017-01-12 2018-09-01 美商優瑞科生物技術公司 靶向組織蛋白h3肽/mhc複合體之構築體及其用途
CA3049456A1 (en) 2017-01-25 2018-08-02 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
MX2019007749A (es) 2017-01-31 2019-09-09 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5.
AR110873A1 (es) 2017-02-10 2019-05-08 Genentech Inc Anticuerpos contra triptasa, composiciones de estos y usos de estos
EP3580235B1 (en) 2017-02-10 2024-05-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
WO2018160841A1 (en) 2017-03-01 2018-09-07 Genentech, Inc. Diagnostic and therapeutic methods for cancer
JP7386083B2 (ja) 2017-03-16 2023-11-24 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｄ８０バリアント免疫調節タンパク質及びその使用
CA3053812A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
CN119161451A (zh) 2017-03-16 2024-12-20 高山免疫科学股份有限公司 Pd-l1变体免疫调节蛋白及其用途
MA49279A (fr) 2017-03-22 2020-02-05 Hoffmann La Roche Compositions d'anticorps optimisées pour le traitement de troubles oculaires
ES3010117T3 (en) 2017-03-27 2025-04-01 Hoffmann La Roche Improved antigen binding receptors
SG10201911225WA (en) 2017-03-28 2020-01-30 Genentech Inc Methods of treating neurodegenerative diseases
EP3601346A1 (en) 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
WO2018178055A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
PE20200010A1 (es) 2017-04-03 2020-01-06 Hoffmann La Roche Anticuerpos que se unen a steap-1
BR112019017753B1 (pt) 2017-04-04 2024-04-30 F. Hoffmann-La Roche Ag Molécula biespecífica de ligação ao antígeno, composição farmacêutica e uso da molécula biespecífica de ligação ao antígeno
TWI690538B (zh) 2017-04-05 2020-04-11 瑞士商赫孚孟拉羅股份公司 特異性結合至pd1至lag3的雙特異性抗體
HRP20221141T1 (hr) 2017-04-05 2022-11-25 F. Hoffmann - La Roche Ag Anti-lag3 protutijela
JP2020516253A (ja) 2017-04-14 2020-06-11 ジェネンテック， インコーポレイテッド がんのための診断及び治療方法
SG11201909048TA (en) 2017-04-21 2019-11-28 Genentech Inc Use of klk5 antagonists for treatment of a disease
AU2018258049B2 (en) 2017-04-26 2025-03-27 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof
EP3615572A1 (en) 2017-04-27 2020-03-04 Tesaro Inc. Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
JP2020518638A (ja) 2017-05-05 2020-06-25 アラコス インコーポレイテッド アレルギー性眼疾患を処置するための方法および組成物
CN113896792B (zh) 2017-05-12 2025-08-22 哈普恩治疗公司 间皮素结合蛋白质
EP3624837B1 (en) 2017-05-16 2025-07-30 Five Prime Therapeutics, Inc. Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
JP2020521791A (ja) 2017-06-02 2020-07-27 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のためのｉｉ型抗ｃｄ２０抗体及び抗ｃｄ２０／ｃｄ３０二重特異性抗体
EA201992502A1 (ru) 2017-06-20 2020-04-22 Эмджен Инк. Способ лечения или уменьшения интенсивности метаболических нарушений с применением белков, связывающих рецептор гастроингибиторного пептида (gipr), в комбинации с агонистами glp-1
MX2020000604A (es) 2017-07-21 2020-09-10 Genentech Inc Métodos terapéuticos y de diagnóstico para el cáncer.
CA3071193A1 (en) 2017-07-26 2019-01-31 Forty Seven, Inc. Anti-sirp-alpha antibodies and related methods
CN110869391A (zh) 2017-07-26 2020-03-06 豪夫迈·罗氏有限公司 用BET抑制剂,Bcl-2抑制剂和抗CD20抗体的组合疗法
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. Anti-cd137 molecules and use thereof
WO2019059411A1 (en) 2017-09-20 2019-03-28 Chugai Seiyaku Kabushiki Kaisha DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
BR112020005834A2 (pt) 2017-09-29 2020-09-24 Chugai Seiyaku Kabushiki Kaisha molécula multiespecífica de ligação ao antígeno tendo atividade de substituição de função de cofator do fator viii de coagulação sanguínea (fviii), e formulação farmacêutica contendo a referida molécula como ingrediente ativo
MA50613A (fr) 2017-10-03 2020-08-12 Editas Medicine Inc Molécules de liaison spécifique à l'hpv
US11753458B2 (en) 2017-10-10 2023-09-12 Alpine Immune Sciences, Inc. CTLA-4 variant immunomodulatory proteins and uses thereof
AU2018347521A1 (en) 2017-10-12 2020-05-07 Immunowake Inc. VEGFR-antibody light chain fusion protein
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
CN111630070B (zh) 2017-10-13 2024-07-30 哈普恩治疗公司 三特异性蛋白质及使用方法
CA3079141A1 (en) 2017-10-17 2019-04-25 Rhizen Pharmaceuticals Sa Crac channel modulators for treating esophageal cancer
TW201925223A (zh) 2017-10-18 2019-07-01 美商艾爾潘免疫科學有限公司 變異型icos 配位體免疫調節蛋白及相關組合物及方法
KR20200067197A (ko) 2017-10-20 2020-06-11 에프. 호프만-라 로슈 아게 단일특이적 항체로부터 다중특이적 항체의 생성 방법
WO2019082124A1 (en) 2017-10-26 2019-05-02 Rhizen Pharmaceuticals Sa COMPOSITION AND METHOD FOR THE TREATMENT OF LARGE B-CELL DIFFUSED LYMPHOMA
CN111629727A (zh) 2017-10-30 2020-09-04 瑞真药业公司 用于治疗血液肿瘤和实体癌的钙释放活化钙通道调节剂
CN111372947B (zh) 2017-10-30 2025-08-15 豪夫迈·罗氏有限公司 在体内从单特异性抗体产生多特异性抗体的方法
AU2018358067A1 (en) 2017-11-01 2020-05-07 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
CA3077664A1 (en) 2017-11-06 2019-05-09 Genentech, Inc. Diagnostic and therapeutic methods for cancer
EP3717516A1 (en) 2017-12-01 2020-10-07 Pfizer Inc Anti-cxcr5 antibodies and compositions and uses thereof
EP3720557A1 (en) 2017-12-06 2020-10-14 Rhizen Pharmaceuticals S.A. Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphoma
JP2021506817A (ja) 2017-12-14 2021-02-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんを治療するための投与計画におけるｃｅａ ｃｄ３二重特異性抗体及びｐｄ−１軸結合アンタゴニストの使用
KR20200110745A (ko) 2017-12-15 2020-09-25 주노 쎄러퓨티크스 인코퍼레이티드 항 - ｃｃｔ5 결합 분자 및 이의 사용 방법
MX2020006119A (es) 2017-12-21 2020-08-24 Hoffmann La Roche Anticuerpos de union a hla-a2/wt1.
KR20200103706A (ko) 2017-12-22 2020-09-02 조운스 테라퓨틱스, 인크. Lilrb2에 대한 항체
WO2019126472A1 (en) 2017-12-22 2019-06-27 Genentech, Inc. Use of pilra binding agents for treatment of a disease
SG11202005273XA (en) 2017-12-28 2020-07-29 Nanjing Legend Biotech Co Ltd Antibodies and variants thereof against pd-l1
CN111699198B (zh) 2017-12-28 2023-09-05 南京传奇生物科技有限公司 针对tigit的单域抗体和其变体
CN111479588A (zh) 2017-12-29 2020-07-31 豪夫迈·罗氏有限公司 用于改善抗vegf抗体的vegf受体阻断选择性的方法
WO2019136029A1 (en) 2018-01-02 2019-07-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
CA3087149A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
CN111818943B (zh) 2018-01-04 2024-09-03 伊科尼克治疗公司 抗组织因子抗体、抗体-药物缀合物及相关方法
EA202091650A1 (ru) 2018-01-05 2020-12-02 Ас Иммьюн Са Неправильно свернутые tdp-43-связывающие молекулы
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
JP7366908B2 (ja) 2018-01-15 2023-10-23 ナンジン レジェンド バイオテック カンパニー，リミテッド Ｐｄ－１に対する単一ドメイン抗体及びその変異体
WO2019143636A1 (en) 2018-01-16 2019-07-25 Lakepharma, Inc. Bispecific antibody that binds cd3 and another target
WO2019148026A1 (en) 2018-01-26 2019-08-01 Genentech, Inc. Il-22 fc fusion proteins and methods of use
HRP20221448T1 (hr) 2018-01-26 2023-01-20 F. Hoffmann - La Roche Ag Il-22 fc pripravci i postupci njihove primjene
TWI800854B (zh) 2018-02-01 2023-05-01 大陸商信達生物製藥（蘇州）有限公司 全人源的抗ｂ細胞成熟抗原（ｂｃｍａ）單鏈抗體及其應用
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
BR112020016169A2 (pt) 2018-02-08 2020-12-15 Genentech, Inc. Moléculas de ligação ao antígeno biespecíficas, ácido nucleico isolado, vetor, célula hospedeira, métodos para produzir a molécula de ligação, conjunto de ácidos nucleicos isolados, conjunto de vetores, conjunto de células hospedeiras, imunoconjugado, composição, uso da molécula de ligação, métodos para tratar ou retardar a progressão de um câncer, métodos para aperfeiçoar a função imune e kit
TWI829667B (zh) 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
EP3749362A1 (en) 2018-02-09 2020-12-16 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
CN111757894B (zh) 2018-02-14 2025-02-25 Abba疗法股份公司 抗人类pd-l2抗体
EP3755713A1 (en) 2018-02-21 2020-12-30 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to hiv-1 env and their use
KR20200123118A (ko) 2018-02-21 2020-10-28 제넨테크, 인크. IL-22 Fc 융합 단백질로 치료를 위한 투약
US20200399376A1 (en) 2018-02-26 2020-12-24 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
CN111683961A (zh) 2018-03-13 2020-09-18 豪夫迈·罗氏有限公司 4-1bb激动剂与抗cd20抗体的治疗剂组合
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CN112166123B (zh) 2018-03-14 2022-09-30 北京轩义医药科技有限公司 抗紧密连接蛋白18.2抗体
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
WO2019177543A1 (en) 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
TWI857954B (zh) 2018-03-29 2024-10-11 美商建南德克公司 調節哺乳動物細胞之生乳活性
CN111886254B (zh) 2018-03-30 2023-12-08 南京传奇生物科技有限公司 针对lag-3的单结构域抗体及其用途
TW202011029A (zh) 2018-04-04 2020-03-16 美商建南德克公司 偵測及定量fgf21之方法
RU2020135968A (ru) 2018-04-05 2022-05-06 Джуно Терапьютикс, Инк. T-клеточные рецепторы и модифицированные клетки, экспрессирующие
IL268443B2 (en) 2018-04-17 2024-07-01 Molecular Templates Inc HER2-targeted molecules containing Shiga toxin subunit A scaffolds, without vaccination
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
AR115052A1 (es) 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
CN110464842B (zh) 2018-05-11 2022-10-14 信达生物制药(苏州)有限公司 包含抗pcsk9抗体的制剂及其用途
JP7497340B2 (ja) 2018-05-14 2024-06-10 ウェアウルフ セラピューティクス， インコーポレイテッド 活性化可能なインターロイキン１２ポリペプチド及びその使用方法
CA3100007A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
CA3102230A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and uses thereof for treating disease or condition
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
JP7372237B2 (ja) 2018-06-04 2023-10-31 中外製薬株式会社 細胞質内での半減期が変化した抗原結合分子
TW202519270A (zh) 2018-06-07 2025-05-16 美商思進公司 喜樹鹼結合物
US12065476B2 (en) 2018-06-15 2024-08-20 Alpine Immune Sciences, Inc. PD-1 variant immunomodulatory proteins and uses thereof
CA3103936A1 (en) 2018-06-18 2019-12-26 Eureka Therapeutics, Inc. Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
EP3810653A1 (en) 2018-06-23 2021-04-28 F. Hoffmann-La Roche AG Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
JP7554742B2 (ja) 2018-07-03 2024-09-20 マレンゴ・セラピューティクス，インコーポレーテッド 抗ｔｃｒ抗体分子およびその使用
EP3818082A1 (en) 2018-07-04 2021-05-12 F. Hoffmann-La Roche AG Novel bispecific agonistic 4-1bb antigen binding molecules
KR20210031679A (ko) 2018-07-09 2021-03-22 밀레니엄 파머슈티컬스 인코퍼레이티드 수모-활성화 효소 저해제 및 항-cd20 항체의 투여
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
BR112021000673A2 (pt) 2018-07-18 2021-04-20 Genentech, Inc. métodos para tratar um indivíduo com câncer de pulmão, kits, anticorpo anti-pd-l1 e composições
MX2021000745A (es) 2018-07-20 2021-03-26 Surface Oncology Inc Composiciones anti-cd112r y metodos.
CN112512563A (zh) 2018-08-01 2021-03-16 中外制药株式会社 用于治疗或预防c5相关疾病的药物组合物和治疗或预防c5相关疾病的方法
SG11202101152QA (en) 2018-08-03 2021-03-30 Chugai Pharmaceutical Co Ltd Antigen-binding molecule containing two antigen-binding domains that are linked to each other
MA50586A (fr) 2018-08-09 2020-09-16 Regeneron Pharma Procédés d'évaluation de l'affinité de liaison d'une variante d'anticorps au récepteur fc néonatal
BR112021002037A2 (pt) 2018-08-10 2021-05-04 Chugai Seiyaku Kabushiki Kaisha molécula de ligação de antígeno anti-cd137 e uso da mesma
TW202021618A (zh) 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
WO2020037258A1 (en) 2018-08-17 2020-02-20 Ab Studio Inc. Catabodies and methods of use thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
CA3110750A1 (en) 2018-09-10 2020-03-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against cd33 and constructs thereof
CN113544144A (zh) 2018-09-19 2021-10-22 高山免疫科学股份有限公司 变体cd80融合蛋白和相关构建体的方法和用途
CA3111401A1 (en) 2018-09-19 2020-03-26 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
WO2020061349A1 (en) 2018-09-21 2020-03-26 Genentech, Inc. Diagnostic methods for triple-negative breast cancer
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
MX2021003554A (es) 2018-09-25 2021-05-27 Harpoon Therapeutics Inc Proteinas de union a dll3 y metodos de uso.
AU2019347751B2 (en) 2018-09-27 2025-05-22 Xilio Development, Inc. Masked cytokine polypeptides
WO2020070035A1 (en) 2018-10-01 2020-04-09 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules with trivalent binding to cd40
CR20210154A (es) 2018-10-01 2021-04-21 Hoffmann La Roche Moléculas de unión a antígeno bioespecíficas que comprenden el clon 212 anti-fap
MY208925A (en) 2018-10-05 2025-06-11 Five Prime Therapeutics Inc Anti-fgfr2 antibody formulations
US20210388101A1 (en) 2018-10-15 2021-12-16 Industry-Academic Cooperation Foundation, Yonsei University Productivity-enhanced antibody and method for producing same
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
MX2021004348A (es) 2018-10-18 2021-05-28 Genentech Inc Procedimientos de diagnóstico y terapéuticos para el cáncer de riñón sarcomatoide.
WO2020089380A1 (en) 2018-10-31 2020-05-07 Bayer Aktiengesellschaft REVERSAL AGENTS FOR NEUTRALIZING THE THERAPEUTIC ACTIVITY OF ANTI-FXIa ANTIBODIES
RU2724469C2 (ru) 2018-10-31 2020-06-23 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с cd20
JP7620546B2 (ja) 2018-11-05 2025-01-23 ジェネンテック， インコーポレイテッド 原核宿主細胞における２鎖タンパク質の産生方法
MX2021005751A (es) 2018-11-16 2021-10-01 Memorial Sloan Kettering Cancer Center Anticuerpos contra mucina 16 y métodos de uso de los mismos.
CN112334483B (zh) 2018-11-27 2022-05-10 信达生物制药(苏州)有限公司 抗IL-23p19抗体及其用途
JP7713886B2 (ja) 2018-11-30 2025-07-28 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｄ８６バリアント免疫調節タンパク質およびその使用
MX2021006578A (es) 2018-12-05 2021-07-07 Genentech Inc Procedimientos de diagnostico y composiciones para la inmunoterapia contra el cancer.
MX2021006573A (es) 2018-12-06 2021-07-15 Genentech Inc Tratamiento conjunto de linfoma difuso de linfocitos b grandes que comprende un inmunoconjugado anti-cd79b, un agente alquilante y un anticuerpo anti-cd20.
CN113227119A (zh) 2018-12-10 2021-08-06 基因泰克公司 用于与含Fc的蛋白质进行位点特异性缀合的光交联肽
JP2022514290A (ja) 2018-12-20 2022-02-10 ジェネンテック， インコーポレイテッド 改変抗体ｆｃおよび使用方法
US20220089694A1 (en) 2018-12-20 2022-03-24 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
EP3898984A1 (en) 2018-12-21 2021-10-27 Genentech, Inc. Methods of producing polypeptides using a cell line resistant to apoptosis
AR117468A1 (es) 2018-12-21 2021-08-11 Hoffmann La Roche ANTICUERPO QUE SE UNE A VEGF Y A IL-1b Y MÉTODOS DE UTILIZACIÓN
KR20210107721A (ko) 2018-12-21 2021-09-01 23앤드미 인코포레이티드 항-il-36 항체 및 이의 사용 방법
US11672858B2 (en) 2018-12-21 2023-06-13 Hoffmann-La Roche Inc. Bispecific antibody molecules binding to CD3 and TYRP-1
AU2019416220A1 (en) 2018-12-26 2021-07-22 Xilio Development, Inc. anti-CTLA4 antibodies and methods of use thereof
JP7650802B2 (ja) 2018-12-30 2025-03-25 エフ． ホフマン－ラ ロシュ アーゲー 抗ウサギｃｄ１９抗体および使用方法
CN115120716A (zh) 2019-01-14 2022-09-30 健泰科生物技术公司 用pd-1轴结合拮抗剂和rna疫苗治疗癌症的方法
WO2020148379A1 (en) 2019-01-17 2020-07-23 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
JP2022522985A (ja) 2019-01-22 2022-04-21 ジェネンテック， インコーポレイテッド 免疫グロブリンａ抗体、並びに産生及び使用の方法
CN113330027B (zh) 2019-01-23 2025-03-28 豪夫迈·罗氏有限公司 在真核宿主细胞中产生多聚体蛋白质的方法
US12263234B2 (en) 2019-01-23 2025-04-01 Tayu Huaxia Biotech Medical Group Co., Ltd. Anti-PD-L1 diabodies and the use thereof
WO2020153467A1 (ja) 2019-01-24 2020-07-30 中外製薬株式会社 新規がん抗原及びそれらの抗原に対する抗体
SG11202107976SA (en) 2019-01-29 2021-08-30 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CN114127111B (zh) 2019-02-21 2024-09-10 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
WO2020176748A1 (en) 2019-02-27 2020-09-03 Genentech, Inc. Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
MX2021010565A (es) 2019-03-08 2021-10-13 Genentech Inc Metodos para detectar y cuantificar proteinas asociadas a la membrana en vesiculas extracelulares.
MX2021010996A (es) 2019-03-14 2021-11-04 Genentech Inc Tratamiento de cancer con anticuerpos biespecificos contra her2xcd3 en combinacion con mab anti-her2.
MX2021012032A (es) 2019-04-01 2021-11-03 Genentech Inc Composiciones y metodos para estabilizar formulaciones que contienen proteinas.
SG11202111349QA (en) 2019-04-12 2021-11-29 Geltor Inc Recombinant elastin and production thereof
BR112021020447A2 (pt) 2019-04-17 2022-05-17 Alpine Immune Sciences Inc Métodos e usos de proteínas de fusão de ligante icos variante (icosl)
EP3956027A1 (en) 2019-04-18 2022-02-23 AC Immune SA Novel molecules for therapy and diagnosis
BR112021020867A2 (pt) 2019-04-19 2022-01-04 Genentech Inc Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração
AU2020257748A1 (en) 2019-04-19 2021-11-18 Chugai Seiyaku Kabushiki Kaisha Chimeric receptor recognizing modification site of antibody
EP3962523A2 (en) 2019-05-03 2022-03-09 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
KR20220004744A (ko) 2019-05-03 2022-01-11 제넨테크, 인크. 항-pd-l1 항체를 이용하여 암을 치료하는 방법
KR20220023988A (ko) 2019-05-14 2022-03-03 웨어울프 세라퓨틱스, 인크. 분리 모이어티 및 이의 사용 방법
BR112021022815A2 (pt) 2019-05-14 2021-12-28 Genentech Inc Métodos para tratar linfoma folicular, kits, imunoconjugados e polatuzumabe vedotina
US20230085439A1 (en) 2019-05-21 2023-03-16 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use
WO2020234473A1 (en) 2019-05-23 2020-11-26 Ac Immune Sa Anti-tdp-43 binding molecules and uses thereof
KR20230011470A (ko) 2019-06-10 2023-01-20 추가이 세이야쿠 가부시키가이샤 사이토카인 저해제와 조합하여 사용하기 위한 항t세포 항원 결합 분자
EP3994173A1 (en) 2019-07-02 2022-05-11 The United States of America, as represented by the Secretary, Department of Health and Human Services Monoclonal antibodies that bind egfrviii and their use
EP3998083A4 (en) 2019-07-12 2023-08-23 Chugai Seiyaku Kabushiki Kaisha ANTI-MUTATION TYPE FGFR3 ANTIBODY AND USE THEREOF
AR119382A1 (es) 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
MX2022001154A (es) 2019-07-31 2022-02-22 Hoffmann La Roche Regimen de dosificacion y administracion para el tratamiento o prevencion de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab.
CN114174338A (zh) 2019-07-31 2022-03-11 豪夫迈·罗氏有限公司 与gprc5d结合的抗体
SG11202112491WA (en) 2019-07-31 2021-12-30 Hoffmann La Roche Antibodies binding to gprc5d
AU2020319677A1 (en) 2019-07-31 2022-01-06 F. Hoffmann-La Roche Ag Dosage and administration regimen for the treatment or prevention of C5-related diseases by the use of the anti-C5 antibody Crovalimab
AU2020325770B2 (en) 2019-08-06 2022-08-25 Aprinoia Therapeutics Limited Antibodies that bind to pathological tau species and uses thereof
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
EP4438056A3 (en) 2019-09-12 2025-01-01 F. Hoffmann-La Roche AG Compositions and methods of treating lupus nephritis
TW202124442A (zh) * 2019-09-13 2021-07-01 大陸商北京軒義醫藥科技有限公司 人源化抗ｃｌｄｎ１８．２抗體、編碼其的核酸分子、其產生方法、包含其的組合物、試劑盒及其用途
PE20221906A1 (es) 2019-09-18 2022-12-23 Genentech Inc Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecificos anti-klk5/klk7 y metodos de uso
CN114423454A (zh) 2019-09-20 2022-04-29 豪夫迈·罗氏有限公司 抗类胰蛋白酶抗体的给药
EP4034160A1 (en) 2019-09-27 2022-08-03 Janssen Biotech, Inc. Anti-ceacam antibodies and uses thereof
PE20221110A1 (es) 2019-09-27 2022-07-11 Genentech Inc Administracion de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
CN114555117A (zh) * 2019-10-12 2022-05-27 百奥泰生物制药股份有限公司 抗cd20抗体制剂及抗cd20抗体在治疗cd20阳性疾病中的应用
CN118557751A (zh) 2019-10-18 2024-08-30 基因泰克公司 使用抗CD79b免疫缀合物治疗弥漫性大B细胞淋巴瘤的方法
JP2023501912A (ja) 2019-10-21 2023-01-20 ライゼン ファーマシューティカルズ アーゲー 急性骨髄性白血病の治療のためのｄｈｏｄｈ阻害剤を含む組成物
US20220389103A1 (en) 2019-11-06 2022-12-08 Genentech, Inc. Diagnostic and therapeutic methods for treatment of hematologic cancers
JP2023503258A (ja) 2019-11-14 2023-01-27 ウェアウルフ セラピューティクス， インコーポレイテッド 活性化可能サイトカインポリペプチド及びその使用方法
KR20220110539A (ko) 2019-12-04 2022-08-08 에이씨 이뮨 에스에이 치료 및 진단용 신규 분자
US20230192869A1 (en) 2019-12-06 2023-06-22 Juno Therapeutics, Inc. Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
BR112022010627A2 (pt) 2019-12-06 2022-08-16 Juno Therapeutics Inc Anticorpos anti-idiotípicos para domínios de ligação alvejados por bcma e composições e métodos relacionados
PE20221511A1 (es) 2019-12-13 2022-10-04 Genentech Inc Anticuerpos anti-ly6g6d y metodos de uso
WO2021122875A1 (en) 2019-12-18 2021-06-24 F. Hoffmann-La Roche Ag Antibodies binding to hla-a2/mage-a4
CN113045655A (zh) 2019-12-27 2021-06-29 高诚生物医药(香港)有限公司 抗ox40抗体及其用途
MY202559A (en) 2019-12-27 2024-05-08 Chugai Pharmaceutical Co Ltd Anti-ctla-4 antibody and use thereof
CA3160204A1 (en) 2020-01-06 2021-07-15 Vaccinex, Inc. Anti-ccr8 antibodies and uses thereof
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2022050954A1 (en) 2020-09-04 2022-03-10 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
EP4096708A1 (en) 2020-01-31 2022-12-07 Genentech, Inc. Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine
CN115768800A (zh) 2020-01-31 2023-03-07 克利夫兰诊所基金会 抗苗勒管激素受体2抗体和使用方法
PE20230168A1 (es) 2020-02-12 2023-02-01 Chugai Pharmaceutical Co Ltd Moleculas de union a antigeno anti-cd137 para su administracion en el tratamiento contra el cancer
MX2022009947A (es) 2020-02-14 2022-11-07 Jounce Therapeutics Inc Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos.
WO2021168292A1 (en) 2020-02-20 2021-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epstein-barr virus monoclonal antibodies and uses thereof
CA3169910A1 (en) 2020-02-28 2021-09-02 Shanghai Henlius Biotech, Inc. Anti-cd137 constructs, multispecific antibody and uses thereof
EP4112642A4 (en) 2020-02-28 2024-06-26 Shanghai Henlius Biotech, Inc. ANTI-CD137 CONSTRUCTION AND ITS USE
EP4114445A1 (en) 2020-03-06 2023-01-11 Ona Therapeutics S.L. Anti-cd36 antibodies and their use to treat cancer
CN115605507A (zh) 2020-03-13 2023-01-13 基因泰克公司（Us） 抗白介素-33抗体及其用途
MX2022011455A (es) 2020-03-19 2022-10-03 Genentech Inc Anticuerpos anti-tgf-beta con selectividad de isoforma y metodos de uso.
MX2022011752A (es) 2020-03-24 2022-10-18 Genentech Inc Agentes de fijacion a tie2 y metodos de uso.
US12098365B2 (en) 2020-03-26 2024-09-24 Genentech, Inc. Modified mammalian cells
CN115397850A (zh) 2020-03-30 2022-11-25 豪夫迈·罗氏有限公司 与vegf和pdgf-b结合的抗体及其使用方法
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
JP2023520515A (ja) 2020-04-03 2023-05-17 ジェネンテック， インコーポレイテッド がんに対する治療方法及び診断方法
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
CN115427443A (zh) 2020-04-24 2022-12-02 豪夫迈·罗氏有限公司 巯基化合物及其衍生物的酶和途径调节
CA3175530A1 (en) 2020-04-24 2021-10-28 Genentech, Inc. Methods of using anti-cd79b immunoconjugates
AU2021262744A1 (en) 2020-04-27 2022-10-06 The Regents Of The University Of California Isoform-independent antibodies to lipoprotein(a)
EP4143345A1 (en) 2020-04-28 2023-03-08 Genentech, Inc. Methods and compositions for non-small cell lung cancer immunotherapy
AU2021267995A1 (en) 2020-05-03 2022-12-08 Levena (Suzhou) Biopharma Co., Ltd. Antibody-drug conjugates (ADCs) comprising an anti-Trop-2 antibody, compositions comprising such ADCs, as well as methods of making and using the same
EP4146684A2 (en) 2020-05-08 2023-03-15 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof
TW202200622A (zh) 2020-05-13 2022-01-01 瑞士商天演藥業公司 用於治療癌症之組成物及方法
CN113993900B (zh) 2020-05-27 2023-08-04 舒泰神（北京）生物制药股份有限公司 特异性识别神经生长因子的抗体及其用途
AU2021281417A1 (en) 2020-05-29 2022-12-08 23Andme, Inc. Anti-CD200R1 antibodies and methods of use thereof
JP2023529842A (ja) 2020-06-02 2023-07-12 ダイナミキュア バイオテクノロジー エルエルシー 抗ｃｄ９３構築物およびその使用
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
MX2022015206A (es) 2020-06-08 2023-01-05 Hoffmann La Roche Anticuerpos anti-hbv y metodos de uso.
WO2021252977A1 (en) 2020-06-12 2021-12-16 Genentech, Inc. Methods and compositions for cancer immunotherapy
JP2023531406A (ja) 2020-06-16 2023-07-24 ジェネンテック， インコーポレイテッド トリプルネガティブ乳がんを処置するための方法および組成物
KR20230024368A (ko) 2020-06-18 2023-02-20 제넨테크, 인크. 항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료
WO2021255146A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
CN115698084A (zh) 2020-06-19 2023-02-03 豪夫迈·罗氏有限公司 与cd3结合的抗体
MX2022016069A (es) 2020-06-19 2023-02-02 Hoffmann La Roche Anticuerpos que se unen a cd3 y cd19.
TW202216767A (zh) 2020-06-19 2022-05-01 瑞士商赫孚孟拉羅股份公司 與ＣＤ３及ＦｏｌＲ１結合之抗體
CA3180951A1 (en) 2020-06-19 2021-12-23 Takayoshi Tanaka Anti-t cell antigen-binding molecule for use in combination with angiogenesis inhibitor
AU2021297856A1 (en) 2020-06-22 2023-02-02 Innovent Biologics (Suzhou) Co., Ltd. Anti-CD73 antibody and use thereof
WO2021259880A1 (en) 2020-06-22 2021-12-30 Almirall, S.A. Anti-il-36 antibodies and methods of use thereof
EP4172192A1 (en) 2020-06-24 2023-05-03 Genentech, Inc. Apoptosis resistant cell lines
US20250262293A1 (en) 2020-07-07 2025-08-21 BioNTech SE Therapeutic rna for hpv-positive cancer
BR112023000204A2 (pt) 2020-07-10 2023-01-31 Hoffmann La Roche Conjunto de anticorpos, conjunto de ácidos nucleicos, vetor de expressão, célula hospedeira, métodos de pré-direcionamento de radioimunoterapia e direcionamento de um radioisótopo, ligante peptídico, proteína de múltiplos domínios e usos
US20230303682A1 (en) 2020-07-17 2023-09-28 Genentech, Inc. Anti-Notch2 Antibodies and Methods of Use
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
TW202221029A (zh) 2020-07-29 2022-06-01 美商當康生物科技有限公司 抗cd93之構築體及其用途
EP4189121A1 (en) 2020-08-03 2023-06-07 Genentech, Inc. Diagnostic and therapeutic methods for lymphoma
JP2023536326A (ja) 2020-08-05 2023-08-24 ジュノー セラピューティクス インコーポレイテッド Ｒｏｒ１標的結合ドメインに対する抗イディオタイプ抗体ならびに関連する組成物および方法
IL300260A (en) 2020-08-07 2023-03-01 Genentech Inc FLT3 ligand fusion proteins and methods of use
CN111759732B (zh) * 2020-08-12 2024-12-06 河南省人民医院 一种用于外周血造血干细胞冻存的多通道连接管路及方法
JP2023537751A (ja) 2020-08-14 2023-09-05 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト オクレリズマブで多発性硬化症を治療するための方法
JP2023537761A (ja) 2020-08-14 2023-09-05 エイシー イミューン ソシエテ アノニム ヒト化抗ｔｄｐ－４３結合分子およびその使用
WO2022043517A2 (en) 2020-08-27 2022-03-03 Cureab Gmbh Anti-golph2 antibodies for macrophage and dendritic cell differentiation
US20230303665A1 (en) 2020-08-28 2023-09-28 Sana Biotechnology, Inc. Modified anti-viral binding agents
TW202227625A (zh) 2020-08-28 2022-07-16 美商建南德克公司 宿主細胞蛋白質之ＣＲＩＳＰＲ／Ｃａｓ９多重剔除
MX2023002496A (es) 2020-09-04 2023-03-09 Hoffmann La Roche Anticuerpo que se une al factor de crecimiento endotelial vascular a (vegf-a) y a la angiopoyetina 2 (ang2) y metodos de uso.
JP2023541627A (ja) 2020-09-14 2023-10-03 イシュノス サイエンシズ ソシエテ アノニム Ｉｌ１ｒａｐに結合する抗体及びその使用
AU2021343834A1 (en) 2020-09-15 2023-04-13 Bayer Aktiengesellschaft Novel anti-A2AP antibodies and uses thereof
JP2023543835A (ja) 2020-09-30 2023-10-18 ドレン バイオ， インコーポレイテッド 抗ｃｄ９４抗体及びその使用方法
KR20230082632A (ko) 2020-10-05 2023-06-08 제넨테크, 인크. 항-fcrh5/항-cd3 이중특이성 항체를 사용한 치료를 위한 투약
CA3198102A1 (en) 2020-10-07 2022-04-14 Dren Bio, Inc. Anti-dectin-1 antibodies and methods of use thereof
EP4229082A1 (en) 2020-10-16 2023-08-23 AC Immune SA Antibodies binding to alpha-synuclein for therapy and diagnosis
KR20230091871A (ko) 2020-10-20 2023-06-23 에프. 호프만-라 로슈 아게 Pd-1 축 결합 길항제 및 lrrk2 억제제의 병용 요법
WO2022086957A1 (en) 2020-10-20 2022-04-28 Genentech, Inc. Peg-conjugated anti-mertk antibodies and methods of use
CA3192306A1 (en) 2020-10-20 2022-04-28 Burkhard Ludewig Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
WO2022098648A2 (en) 2020-11-04 2022-05-12 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
EP4240766A2 (en) 2020-11-04 2023-09-13 Genentech, Inc. Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
EP4240492A2 (en) 2020-11-04 2023-09-13 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
US20220143026A1 (en) 2020-11-12 2022-05-12 Tg Therapeutics, Inc. Triple combination to treat b-cell malignancies
EP4251187A4 (en) 2020-11-25 2025-09-10 Xilio Dev Inc TUMOR-SPECIFIC CLASSIBLE LINKERS
CN116802211A (zh) 2020-12-07 2023-09-22 Ucb生物制药有限责任公司 针对白介素-22的抗体
CN116670166A (zh) 2020-12-07 2023-08-29 Ucb生物制药有限责任公司 多特异性抗体和抗体组合
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
IL303656A (en) 2020-12-17 2023-08-01 Hoffmann La Roche Anti-hla-g antibodies and use thereof
WO2022132904A1 (en) 2020-12-17 2022-06-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies targeting sars-cov-2
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135467A1 (zh) 2020-12-23 2022-06-30 信达生物制药(苏州)有限公司 抗b7-h3抗体及其用途
WO2022140797A1 (en) 2020-12-23 2022-06-30 Immunowake Inc. Immunocytokines and uses thereof
JP2024503826A (ja) 2021-01-06 2024-01-29 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ１－ｌａｇ３二重特異性抗体及びｃｄ２０ ｔ細胞二重特異性抗体を用いる併用療法
AU2022207615A1 (en) 2021-01-12 2023-07-13 F. Hoffmann-La Roche Ag Split antibodies which bind to cancer cells and target radionuclides to said cells
MX2023008083A (es) 2021-01-13 2023-07-13 Hoffmann La Roche Tratamiento conjunto.
JP2024504493A (ja) 2021-01-28 2024-01-31 ヴァクスィーンヴェント ゲーエムベーハー Ｂ細胞媒介性免疫応答を調節するための方法及び手段
WO2022162203A1 (en) 2021-01-28 2022-08-04 Vaccinvent Gmbh Method and means for modulating b-cell mediated immune responses
CN117120084A (zh) 2021-01-28 2023-11-24 维肯芬特有限责任公司 用于调节b细胞介导的免疫应答的方法和手段
EP4288455A1 (en) 2021-02-03 2023-12-13 Mozart Therapeutics, Inc. Binding agents and methods of using the same
WO2022169872A1 (en) 2021-02-03 2022-08-11 Genentech, Inc. Multispecific binding protein degrader platform and methods of use
JP2024506315A (ja) 2021-02-09 2024-02-13 ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ コロナウイルスのスパイクタンパク質を標的とする抗体
US20240117019A1 (en) 2021-02-09 2024-04-11 University Of Georgia Research Foundation, Inc. Human monoclonal antibodies against pneumococcal antigens
JP2024506200A (ja) 2021-02-15 2024-02-09 武田薬品工業株式会社 細胞治療用組成物及びｔｇｆ－ｂシグナル伝達を調節する方法
WO2022180172A1 (en) 2021-02-26 2022-09-01 Bayer Aktiengesellschaft Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding
US20220306743A1 (en) 2021-03-01 2022-09-29 Xilio Development, Inc. Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
CA3209364A1 (en) 2021-03-01 2022-09-09 Jennifer O'neil Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
CN117440832A (zh) 2021-03-03 2024-01-23 索伦托药业有限公司 包括抗bcma抗体的抗体-药物缀合物
JP2024509191A (ja) 2021-03-05 2024-02-29 ダイナミキュア バイオテクノロジー エルエルシー 抗ｖｉｓｔａ構築物およびその使用
EP4294927A2 (en) 2021-03-10 2023-12-27 Immunowake Inc. Immunomodulatory molecules and uses thereof
EP4304732A1 (en) 2021-03-12 2024-01-17 Genentech, Inc. Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
MX2023010812A (es) 2021-03-15 2023-09-27 Genentech Inc Composiciones y metodos para tratar la nefritis lupica.
WO2022197877A1 (en) 2021-03-19 2022-09-22 Genentech, Inc. Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
WO2022204724A1 (en) 2021-03-25 2022-09-29 Dynamicure Biotechnology Llc Anti-igfbp7 constructs and uses thereof
MX2023011619A (es) 2021-03-30 2023-10-11 Bayer Ag Nuevos anticuerpos anti-sema3a y usos de los mismos.
CN117279664A (zh) 2021-04-10 2023-12-22 普方生物制药美国公司 Folr1结合剂、其偶联物及其使用方法
AR125344A1 (es) 2021-04-15 2023-07-05 Chugai Pharmaceutical Co Ltd Anticuerpo anti-c1s
KR20230173164A (ko) 2021-04-19 2023-12-26 제넨테크, 인크. 변형된 포유류 세포
WO2022226317A1 (en) 2021-04-23 2022-10-27 Profoundbio Us Co. Anti-cd70 antibodies, conjugates thereof and methods of using the same
CN117222412A (zh) 2021-04-23 2023-12-12 豪夫迈·罗氏有限公司 Nk细胞接合剂相关的不良反应的预防或减轻
EP4329800A1 (en) 2021-04-30 2024-03-06 F. Hoffmann-La Roche AG Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
CA3213632A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
CA3218933A1 (en) 2021-05-03 2022-11-10 UCB Biopharma SRL Antibodies
JP2024518410A (ja) 2021-05-07 2024-05-01 ビエラ バイオ インコーポレイテッド 重症筋無力症を治療するための抗ｃｄ１９抗体の使用
EP4333869A1 (en) 2021-05-07 2024-03-13 Alpine Immune Sciences, Inc. Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
EP4337266A1 (en) 2021-05-12 2024-03-20 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
BR112023023777A2 (pt) 2021-05-14 2024-01-30 Genentech Inc Anticorpos isolados, composição farmacêutica, ácido nucleico isolado, vetor isolado, célula hospedeira isolada, método para produzir um anticorpo, método para tratar uma condição associada à perda de função de trem2, método para reduzir os níveis de strem2 e uso de um anticorpo
JP2023546368A (ja) 2021-05-14 2023-11-02 ジェネンテック， インコーポレイテッド モスネツズマブおよびポラツズマブベドチンを用いたｃｄ２０陽性増殖性障害の処置のための方法
WO2022243347A1 (en) * 2021-05-18 2022-11-24 Christian-Albrechts-Universität Zu Kiel Co-stimulatory multispecific antibodies
WO2022243261A1 (en) 2021-05-19 2022-11-24 F. Hoffmann-La Roche Ag Agonistic cd40 antigen binding molecules targeting cea
WO2022246259A1 (en) 2021-05-21 2022-11-24 Genentech, Inc. Modified cells for the production of a recombinant product of interest
CN117480184A (zh) 2021-06-04 2024-01-30 中外制药株式会社 抗ddr2抗体及其用途
JP2024521579A (ja) 2021-06-09 2024-06-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療における使用のための特定のｂｒａｆ阻害剤（パラドックスブレーカー）とｐｄ－１軸結合アンタゴニストとの組み合わせ
WO2022262808A1 (en) * 2021-06-16 2022-12-22 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric cd20 genes
US12227574B2 (en) 2021-06-17 2025-02-18 Amberstone Biosciences, Inc. Anti-CD3 constructs and uses thereof
WO2022266540A2 (en) 2021-06-18 2022-12-22 Therini Bio, Inc. ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE
KR102690145B1 (ko) 2021-06-25 2024-07-30 추가이 세이야쿠 가부시키가이샤 항ctla-4 항체의 사용
BR112023022992A2 (pt) 2021-06-25 2024-01-23 Chugai Pharmaceutical Co Ltd Anticorpo anti-ctla-4
TW202309078A (zh) 2021-07-02 2023-03-01 美商建南德克公司 治療癌症之方法及組成物
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
WO2023283611A1 (en) 2021-07-08 2023-01-12 Staidson Biopharma Inc. Antibodies specifically recognizing tnfr2 and uses thereof
WO2023288182A1 (en) 2021-07-12 2023-01-19 Genentech, Inc. Structures for reducing antibody-lipase binding
WO2023285552A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
JP2024527606A (ja) 2021-07-14 2024-07-25 ジェネンテック， インコーポレイテッド 抗ｃ－ｃモチーフケモカイン受容体８（ｃｃｒ８）抗体及び使用方法
JP2024525769A (ja) 2021-07-14 2024-07-12 舒泰神（北京）生物製薬股フン有限公司 Ｃｄ４０を特異的に認識する抗体およびその使用
EP4373576A1 (en) 2021-07-22 2024-05-29 Genentech, Inc. Brain targeting compositions and methods of use thereof
EP4373859A1 (en) 2021-07-22 2024-05-29 F. Hoffmann-La Roche AG Heterodimeric fc domain antibodies
AU2022317820A1 (en) 2021-07-28 2023-12-14 F. Hoffmann-La Roche Ag Methods and compositions for treating cancer
CN118488964A (zh) 2021-07-30 2024-08-13 Ona疗法有限公司 抗cd36抗体及其治疗癌症的用途
EP4382538A1 (en) 2021-08-02 2024-06-12 Innovent Biologics (Suzhou) Co., Ltd. Anti-cd79b×cd3 bispecific antibody and use thereof
JP2024528217A (ja) 2021-08-03 2024-07-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗体および使用方法
US20240336697A1 (en) 2021-08-07 2024-10-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
CN117897409A (zh) 2021-08-13 2024-04-16 基因泰克公司 抗类胰蛋白酶抗体的给药
WO2023021055A1 (en) 2021-08-19 2023-02-23 F. Hoffmann-La Roche Ag Multivalent anti-variant fc-region antibodies and methods of use
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
EP4392451A1 (en) 2021-08-23 2024-07-03 Immunitas Therapeutics, Inc. Anti-cd161 antibodies and uses thereof
EP4392067A1 (en) 2021-08-27 2024-07-03 Genentech, Inc. Methods of treating tau pathologies
JP2024534853A (ja) 2021-08-30 2024-09-26 ジェネンテック， インコーポレイテッド 抗ポリビキチン多重特異性抗体
KR20240058167A (ko) 2021-09-17 2024-05-03 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Sars-cov-2 중화 항체 동정을 위한 합성 인간화 라마 나노바디 라이브러리 및 이의 용도
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
EP4413998A1 (en) 2021-10-08 2024-08-14 Chugai Seiyaku Kabushiki Kaisha Method for preparing prefilled syringe formulation
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
US20250251400A1 (en) 2021-11-05 2025-08-07 American Diagnostics & Therapy, Llc (Adxrx) Monoclonal Antibodies Against Carcinoembryonic Antigens, and Their Uses
JP2024544885A (ja) 2021-11-10 2024-12-05 ジェネンテック， インコーポレイテッド 抗インターロイキン－３３抗体及びその使用
MX2024005680A (es) 2021-11-16 2024-05-30 Genentech Inc Metodos y composiciones para tratar lupus eritematoso sistemico (sle) con mosunetuzumab.
KR20240100369A (ko) 2021-11-16 2024-07-01 에이씨 이뮨 에스에이 치료 및 진단을 위한 신규한 분자
EP4437006A1 (en) 2021-11-26 2024-10-02 F. Hoffmann-La Roche AG Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodies
WO2023103788A1 (zh) 2021-12-06 2023-06-15 北京三诺佳邑生物技术有限责任公司 特异性结合肺炎克雷伯菌o2抗原和o1抗原的双特异性抗体以及组合物
AR127887A1 (es) 2021-12-10 2024-03-06 Hoffmann La Roche Anticuerpos que se unen a cd3 y plap
TW202330582A (zh) 2021-12-15 2023-08-01 美商建南德克公司 穩定的ｉｌ－１８多肽及其用途
WO2023109900A1 (en) 2021-12-17 2023-06-22 Shanghai Henlius Biotech, Inc. Anti-ox40 antibodies, multispecific antibodies and methods of use
KR20240122784A (ko) 2021-12-17 2024-08-13 상하이 헨리우스 바이오테크, 인크. 항-ox40 항체 및 사용 방법
CR20240246A (es) 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
PE20242347A1 (es) 2022-01-07 2024-12-16 Johnson And Johnson Entpr Innovation Inc Materiales y metodos de proteinas de union a il-1 beta
TW202340251A (zh) 2022-01-19 2023-10-16 美商建南德克公司 抗ｎｏｔｃｈ２抗體及結合物及其使用方法
AU2023217695A1 (en) * 2022-02-08 2024-08-15 Amgen Inc. Codon-optimized nucleic acids encoding ocrelizumab
JP2025506172A (ja) 2022-02-10 2025-03-07 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ コロナウイルスを広く標的とするヒトモノクローナル抗体
JP2025507569A (ja) 2022-02-16 2025-03-21 エイシー イミューン ソシエテ アノニム ヒト化抗ｔｄｐ－４３結合分子およびその使用
AU2023221861A1 (en) 2022-02-18 2024-09-05 Rakuten Medical, Inc. Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use
EP4490173A1 (en) 2022-03-07 2025-01-15 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
JP2025509286A (ja) 2022-03-10 2025-04-11 ビバソル， インコーポレイテッド 抗体－薬物コンジュゲートおよびその使用
KR20250005568A (ko) 2022-03-18 2025-01-09 이볼브이뮨 테라퓨틱스, 인크. 이중특이성 항체 융합 분자 및 이의 사용 방법
JP2025512785A (ja) 2022-03-23 2025-04-22 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃｄ２０／抗ｃｄ３二重特異性抗体及び化学療法の併用処置
WO2023179740A1 (en) 2022-03-25 2023-09-28 Shanghai Henlius Biotech , Inc. Anti-msln antibodies and methods of use
WO2023192827A1 (en) 2022-03-26 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bispecific antibodies to hiv-1 env and their use
WO2023192881A1 (en) 2022-03-28 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
WO2023186756A1 (en) 2022-03-28 2023-10-05 F. Hoffmann-La Roche Ag Interferon gamma variants and antigen binding molecules comprising these
WO2023191816A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023194565A1 (en) 2022-04-08 2023-10-12 Ac Immune Sa Anti-tdp-43 binding molecules
KR20250004776A (ko) 2022-04-13 2025-01-08 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이성 항체의 약학 조성물 및 사용 방법
JP2025512342A (ja) 2022-04-13 2025-04-17 ジェネンテック， インコーポレイテッド 治療用タンパク質の医薬組成物および使用方法
WO2023203177A1 (en) 2022-04-20 2023-10-26 Kantonsspital St. Gallen Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
EP4519322A1 (en) 2022-05-03 2025-03-12 Genentech, Inc. Anti-ly6e antibodies, immunoconjugates, and uses thereof
WO2023217068A1 (zh) 2022-05-09 2023-11-16 舒泰神（北京）生物制药股份有限公司 特异性识别gdf15的抗体及其应用
CN119317641A (zh) 2022-05-11 2025-01-14 基因泰克公司 针对用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
AR129268A1 (es) 2022-05-11 2024-08-07 Hoffmann La Roche Anticuerpo que se une a vegf-a e il6 y métodos de uso
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
AU2023284422A1 (en) 2022-06-07 2024-12-19 Genentech, Inc. Method for determining the efficacy of a lung cancer treatment comprising an anti-pd-l1 antagonist and an anti-tigit antagonist antibody
EP4536290A1 (en) 2022-06-08 2025-04-16 Angiex, Inc. Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
WO2023237706A2 (en) 2022-06-08 2023-12-14 Institute For Research In Biomedicine (Irb) Cross-specific antibodies, uses and methods for discovery thereof
AU2023305619A1 (en) 2022-07-13 2025-01-23 F. Hoffmann-La Roche Ag Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
EP4558226A1 (en) 2022-07-19 2025-05-28 Staidson Biopharma Inc. Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
WO2024020432A1 (en) 2022-07-19 2024-01-25 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
AU2023312051A1 (en) 2022-07-22 2025-01-09 Genentech, Inc. Anti-steap1 antigen-binding molecules and uses thereof
EP4565329A1 (en) 2022-08-01 2025-06-11 The United States of America, as represented by the Secretary, Department of Health and Human Services Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
WO2024030956A2 (en) 2022-08-03 2024-02-08 Mozart Therapeutics, Inc. Cd39-specific binding agents and methods of using the same
WO2024028732A1 (en) 2022-08-05 2024-02-08 Janssen Biotech, Inc. Cd98 binding constructs for treating brain tumors
MA71684A (fr) 2022-08-05 2025-05-30 Janssen Biotech, Inc. Protéines de liaison de récepteur de transferrine pour traitement de tumeurs cérébrales
KR20250049554A (ko) 2022-08-19 2025-04-11 이바이브 바이오테크놀로지 (상하이) 엘티디 G-csf를 포함하는 제형 및 이의 용도
JP2025529896A (ja) 2022-08-22 2025-09-09 アブデラ セラピューティクス インク． Ｄｌｌ３結合分子およびその使用
EP4577235A2 (en) 2022-08-26 2025-07-02 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
WO2024049949A1 (en) 2022-09-01 2024-03-07 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
WO2024054822A1 (en) 2022-09-07 2024-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered sars-cov-2 antibodies with increased neutralization breadth
EP4584296A1 (en) 2022-09-07 2025-07-16 Dynamicure Biotechnology LLC Anti-vista constructs and uses thereof
WO2024064826A1 (en) 2022-09-22 2024-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
CN119998321A (zh) 2022-09-27 2025-05-13 舒泰神（北京）生物制药股份有限公司 特异性识别light的抗体及其应用
CN120344256A (zh) 2022-10-04 2025-07-18 高山免疫科学股份有限公司 突变的taci-fc融合蛋白用于在治疗自身抗体介导的疾病中的用途
WO2024077239A1 (en) 2022-10-07 2024-04-11 Genentech, Inc. Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
WO2024083021A1 (zh) 2022-10-20 2024-04-25 北京三诺佳邑生物技术有限责任公司 特异性结合TRAIL或FasL的抗体组合以及双特异性抗体
EP4609201A1 (en) 2022-10-25 2025-09-03 Genentech, Inc. Therapeutic and diagnostic methods for multiple myeloma
EP4612178A1 (en) 2022-11-03 2025-09-10 F. Hoffmann-La Roche AG Combination therapy with anti-cd19/anti-cd28 bispecific antibody
AU2023373363A1 (en) 2022-11-04 2025-05-08 Gilead Sciences, Inc. Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations
KR20250099701A (ko) 2022-11-08 2025-07-02 제넨테크, 인크. 소아기 발병 특발성 신증후군의 치료 조성물 및 치료 방법
WO2024100200A1 (en) 2022-11-09 2024-05-16 Cis Pharma Ag Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications
WO2024100170A1 (en) 2022-11-11 2024-05-16 F. Hoffmann-La Roche Ag Antibodies binding to hla-a*02/foxp3
WO2024108053A1 (en) 2022-11-17 2024-05-23 Sanofi Ceacam5 antibody-drug conjugates and methods of use thereof
WO2024111657A1 (ja) 2022-11-25 2024-05-30 中外製薬株式会社 タンパク質の製造方法
CN119546630A (zh) 2022-12-08 2025-02-28 南京诺唯赞生物科技股份有限公司 特异性结合rsv的抗体
KR20250120305A (ko) 2022-12-14 2025-08-08 아스텔라스 파마 유럽 비.브이. Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법
WO2024137381A1 (en) 2022-12-19 2024-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies for treating sars-cov-2 infection
WO2024145398A1 (en) 2022-12-27 2024-07-04 Yale University Antibody drug conjugates
AR131638A1 (es) 2023-01-18 2025-04-16 Genentech Inc Anticuerpos multiespecíficos y usos de estos
WO2024158824A1 (en) 2023-01-23 2024-08-02 Yale University Antibody oligonucleotide conjugates
CN120569410A (zh) 2023-01-25 2025-08-29 豪夫迈·罗氏有限公司 与csf1r和cd3结合的抗体
WO2024163009A1 (en) 2023-01-31 2024-08-08 Genentech, Inc. Methods and compositions for treating urothelial bladder cancer
WO2024163494A1 (en) 2023-01-31 2024-08-08 F. Hoffmann-La Roche Ag Methods and compositions for treating non-small cell lung cancer and triple-negative breast cancer
WO2024173607A2 (en) 2023-02-14 2024-08-22 Evolveimmune Therapeutics, Inc. Combination of bispecific antibodies and chimeric antigen receptor t cells for treatment
US20240368250A1 (en) 2023-02-17 2024-11-07 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
WO2024184494A1 (en) 2023-03-08 2024-09-12 Ac Immune Sa Anti-tdp-43 binding molecules and uses thereof
WO2024191785A1 (en) 2023-03-10 2024-09-19 Genentech, Inc. Fusions with proteases and uses thereof
WO2024188965A1 (en) 2023-03-13 2024-09-19 F. Hoffmann-La Roche Ag Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
WO2024197302A1 (en) 2023-03-23 2024-09-26 Yale University Compositions and methods for delivering antibody oligonucleotide conjugates for exon skipping
WO2024206788A1 (en) 2023-03-31 2024-10-03 Genentech, Inc. Anti-alpha v beta 8 integrin antibodies and methods of use
WO2024211234A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024211235A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024211236A2 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024212827A1 (en) 2023-04-12 2024-10-17 Shanghai Kangabio Co., Limited Multifunctional molecules comprising masked interleukin 12 and methods of use
WO2024220546A2 (en) 2023-04-17 2024-10-24 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
TW202448949A (zh) 2023-05-05 2024-12-16 美商建南德克公司 用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥
WO2024231320A1 (en) 2023-05-08 2024-11-14 F. Hoffmann-La Roche Ag Targeted interferon alpha fusion proteins and methods of use
WO2024233646A1 (en) 2023-05-10 2024-11-14 Genentech, Inc. Methods and compositions for treating cancer
WO2024238537A1 (en) 2023-05-16 2024-11-21 F. Hoffmann-La Roche Ag Pd-1 -regulated il-2 immunocytokine and uses thereof
WO2024243423A1 (en) 2023-05-24 2024-11-28 Mozart Therapeutics, Inc. Cd8-specific binding proteins and methods of using the same
WO2024243355A1 (en) 2023-05-24 2024-11-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that target the rh5 complex of blood-stage plasmodium falciparum
TW202448953A (zh) 2023-06-01 2024-12-16 法商皮爾法伯製藥公司 用於腫瘤及轉移之治療的基於沉默抗體的抗met建構物
TW202504641A (zh) 2023-06-08 2025-02-01 美商建南德克公司 用於淋巴瘤之診斷及治療方法的巨噬細胞特徵
TW202504929A (zh) 2023-06-22 2025-02-01 美商建南德克公司 用於癌症治療之方法及組成物
TW202502809A (zh) 2023-06-22 2025-01-16 美商建南德克公司 抗體及其用途
WO2024263195A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2024263904A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2025002410A1 (en) 2023-06-30 2025-01-02 Evive Biotechnology (Shanghai) Ltd G-csf dimer for use in the treatment or prevention of chemotherapy or radiotherapy induced neutropenia
WO2025014896A1 (en) 2023-07-07 2025-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Humanized 40h3 antibody
TW202517294A (zh) 2023-07-11 2025-05-01 美商建南德克公司 用於治療多發性硬化症之組成物及方法
WO2025024233A1 (en) 2023-07-21 2025-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bispecific antibodies that broadly target coronaviruses
WO2025021838A1 (en) 2023-07-26 2025-01-30 F. Hoffmann-La Roche Ag Antibodies binding to cd3
WO2025027052A1 (en) 2023-07-31 2025-02-06 Sixpeaks Bio Ag Antibody conjugates and fusion proteins
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein
WO2025032069A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032071A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032070A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Anti-a-beta protein antibodies, methods and uses thereof
WO2025038492A1 (en) 2023-08-11 2025-02-20 Abalytics Oncology, Inc. Anti-ctla-4 antibodies and related binding molecules and methods and uses thereof
WO2025049905A1 (en) 2023-09-01 2025-03-06 Gennao Bio, Inc. Dnase co-expression in host cells
WO2025045250A1 (en) 2023-09-03 2025-03-06 Kira Pharmaceuticals (Us) Llc Anti-human factor d antibody constructs and uses thereof
WO2025054500A2 (en) 2023-09-08 2025-03-13 Mlab Biosciences, Inc. Bifunctional proteins and uses thereof
WO2025059037A1 (en) 2023-09-11 2025-03-20 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules targeting b7-h4 and cd3 and methods of use thereof
WO2025064539A1 (en) 2023-09-19 2025-03-27 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Herv-e antibodies and methods of their use
WO2025064885A1 (en) 2023-09-20 2025-03-27 Evolveimmune Therapeutics, Inc. Multispecific antibodies that bind cd3 and cd2 and methods of use thereof
WO2025064890A1 (en) 2023-09-20 2025-03-27 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules targeting cd180 and cd3 and methods of use thereof
TW202517673A (zh) 2023-09-25 2025-05-01 瑞士商赫孚孟拉羅股份公司 與Ｃ３ｂＢｂ結合之抗體
WO2025072406A1 (en) 2023-09-26 2025-04-03 Profoundbio Us Co. Ptk7 binding agents, conjugates thereof and methods of using the same
TW202517674A (zh) 2023-10-19 2025-05-01 德商拜耳廠股份有限公司 抗gpc3抗體及其放射性結合物
WO2025099120A1 (en) 2023-11-09 2025-05-15 F. Hoffmann-La Roche Ag Multispecific antibodies with conditional activity
WO2025106427A1 (en) 2023-11-14 2025-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)
WO2025106474A1 (en) 2023-11-14 2025-05-22 Genentech, Inc. Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
WO2025111402A1 (en) 2023-11-21 2025-05-30 Board Of Regents Of The University Of Nebraska Anti-amyloid beta antibodies and related compositions and methods thereof
WO2025117639A1 (en) 2023-11-27 2025-06-05 Profoundbio Us Co. Antibodies and methods for ptk7 detection
WO2025117516A1 (en) 2023-11-30 2025-06-05 Genzyme Corporation Methods for treating cd20-related disorders
WO2025117384A1 (en) 2023-12-01 2025-06-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing influenza hemagglutinin stem-directed antibodies
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025125118A1 (en) 2023-12-11 2025-06-19 F. Hoffmann-La Roche Ag Protease activatable fc domain binding molecules
WO2025125386A1 (en) 2023-12-14 2025-06-19 F. Hoffmann-La Roche Ag Antibodies that bind to folr1 and methods of use
WO2025137410A1 (en) 2023-12-20 2025-06-26 Apogee Therapeutics, Inc. Pharmaceutical compositions of anti-il-13 antibodies with and without c-terminal lysine
WO2025137523A2 (en) 2023-12-20 2025-06-26 Apogee Therapeutics, Inc. Pharmaceutical formulations of antibodies that bind interleukin 13
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods
WO2025132503A1 (en) 2023-12-20 2025-06-26 F. Hoffmann-La Roche Ag Antibodies binding to ceacam5
WO2025133290A1 (en) 2023-12-21 2025-06-26 Temper Bio Protein for immune regulation
WO2025137284A2 (en) 2023-12-21 2025-06-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing antibodies against sars-cov-2 and sars-cov variants
WO2025133042A2 (en) 2023-12-22 2025-06-26 F. Hoffmann-La Roche Ag Activatable fusion proteins and methods of use
WO2025149661A1 (en) 2024-01-10 2025-07-17 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
WO2025149633A1 (en) 2024-01-12 2025-07-17 Laigo Bio B.V. Bispecific antigen binding proteins
WO2025179281A1 (en) 2024-02-23 2025-08-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Treatment of cardiovascular disease with antxr1 antibodies
WO2025184416A1 (en) 2024-02-27 2025-09-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single-domain antibodies and bispecific antibodies against hiv-1 and their use
WO2025184421A1 (en) 2024-02-28 2025-09-04 Juno Therapeutics, Inc. Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods
WO2025181219A1 (en) 2024-02-29 2025-09-04 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
WO2025181189A1 (en) 2024-03-01 2025-09-04 F. Hoffmann-La Roche Ag Antibodies binding to cd3

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002128A (en) * 1934-02-19 1935-05-21 Ray A Reidenbaugh Display rack
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989008114A1 (en) 1988-02-25 1989-09-08 The General Hospital Corporation Rapid immunoselection cloning method
US5506126A (en) 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
US4861579A (en) 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
FI891226L (fi) 1988-04-28 1989-10-29 Univ Leland Stanford Junior Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1990008187A1 (en) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
EP0463101B2 (en) 1989-03-21 2003-03-19 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
KR100216097B1 (ko) 1989-07-19 1999-08-16 크리스토퍼 제이. 마골린 자가면역 및 악성종양질환 치료제로서의 t세포 수용체 펩티드
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5417972A (en) 1993-08-02 1995-05-23 The Board Of Trustees Of The Leland Stanford Junior University Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US20010056066A1 (en) 1996-07-26 2001-12-27 Smithkline Beecham Corporation Method of treating immune cell mediated systemic diseases
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
DK0999853T3 (da) 1997-06-13 2003-04-22 Genentech Inc Stabiliseret antostofformulering
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
EP0994903B1 (en) 1997-06-24 2005-05-25 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
WO1999002567A2 (en) 1997-07-08 1999-01-21 Board Of Regents, The University Of Texas System Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
JP2001521909A (ja) 1997-10-31 2001-11-13 ジェネンテク・インコーポレイテッド 糖タンパク質グリコフォームを含む方法及び組成物
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
WO2000009160A1 (en) * 1998-08-11 2000-02-24 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
US6224866B1 (en) 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
DE69942727D1 (de) 1998-11-09 2010-10-14 Biogen Idec Inc Chimärer anti-CD20 Antikörper, Rituxan, zur Verwendung in der Behandlung der chronischen lymphatischen Leukemie
TR200101302T2 (tr) 1998-11-09 2001-10-22 Idec Pharmaceuticals Corporation BMT yada PBSC transplantı alan hastalarda in vitro ya da in vivo temizleyici madde olarak kimerik anti-CD20 antikorunun kullanımı.
EP2366713A3 (en) 1999-01-15 2012-06-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
US6383276B1 (en) 1999-03-12 2002-05-07 Fuji Photo Film Co., Ltd. Azomethine compound and oily magenta ink
PL200134B1 (pl) 1999-05-07 2008-12-31 Genentech Inc Zastosowanie przeciwciała anty-CD20
PT1194167E (pt) 1999-06-09 2009-10-23 Immunomedics Inc Imunoterapia de doenças auto-imunitárias utilizando anticorpos que têm como alvo células b
ITMI991299A1 (it) * 1999-06-11 2000-12-11 Consiglio Nazionale Ricerche Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
DE19930748C2 (de) 1999-07-02 2001-05-17 Infineon Technologies Ag Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip
PL201086B1 (pl) 1999-07-12 2009-03-31 Genentech Inc Zastosowanie przeciwciał wiążących się z antygenem CD20
EP1207906A4 (en) 1999-08-11 2005-07-06 Biogen Idec Inc TREATMENT OF NON-HODGKIN LYMPHOMA PATIENTS WITH BONE MARROW WITH INVOLVEMENT OF ANTI-CD20 ANTIBODIES
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US6451284B1 (en) 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
AU6929100A (en) * 1999-08-23 2001-03-19 Biocrystal Limited Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
EP1229935A1 (en) 1999-11-08 2002-08-14 Idec Pharmaceuticals Corporation Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20030185796A1 (en) 2000-03-24 2003-10-02 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
CA2404390A1 (en) 2000-03-24 2001-10-04 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2
WO2001074388A1 (en) 2000-03-31 2001-10-11 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
CA2405632A1 (en) 2000-04-25 2001-11-01 Idec Pharmaceutical Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
AU6836301A (en) 2000-06-20 2002-01-02 Idec Pharma Corp Treatment of b-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
JP2003535907A (ja) 2000-06-22 2003-12-02 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 抗体誘導性細胞溶解を促進し、そして癌を処置するための方法
KR20080039547A (ko) 2000-07-12 2008-05-07 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 고갈 항체 및 면역 조절 항체 관련 적용의 조합을이용한 ｂ 세포 악성종양의 치료
JP2004508420A (ja) * 2000-09-18 2004-03-18 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法
US20020128448A1 (en) * 2000-10-20 2002-09-12 Idec Pharmaceuticals Corporation Variant IgG3 Rituxan and therapeutic use thereof
KR20100031769A (ko) 2000-12-28 2010-03-24 알투스 파마슈티컬스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
IL157142A0 (en) 2001-01-29 2004-02-08 Idec Pharma Corp Modified antibodies and methods of use
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US20030103971A1 (en) 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20030003097A1 (en) 2001-04-02 2003-01-02 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with GnTIII
EP2359849A1 (en) 2001-04-02 2011-08-24 Genentech, Inc. Combination therapy
WO2003061694A1 (en) 2001-05-10 2003-07-31 Seattle Genetics, Inc. Immunosuppression of the humoral immune response by anti-cd20 antibodies
AU2002315168A1 (en) 2001-06-14 2003-01-02 Intermune, Inc. Combination therapy of gamma-interferon and b cell specific antibodies
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US7718387B2 (en) 2001-09-20 2010-05-18 Board Of Regents, The University Of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
ES2326964T3 (es) 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
US7127096B2 (en) * 2001-11-20 2006-10-24 Accuimage Diagnostics Corp. Method and software for improving coronary calcium scoring consistency
WO2003049694A2 (en) 2001-12-07 2003-06-19 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP1519959B1 (en) 2002-02-14 2014-04-02 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
US20040002587A1 (en) * 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20030180292A1 (en) 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
US20030219818A1 (en) 2002-05-10 2003-11-27 Bohen Sean P. Methods and compositions for determining neoplastic disease responsiveness to antibody therapy
CA2494104A1 (en) 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
WO2004035607A2 (en) 2002-10-17 2004-04-29 Genmab A/S Human monoclonal antibodies against cd20
JP4351674B2 (ja) 2002-12-16 2009-10-28 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体とその使用法およびその使用
WO2004091657A2 (en) * 2003-04-09 2004-10-28 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
BRPI0510915A (pt) * 2004-06-04 2007-11-13 Genentech Inc método para o tratamento da esclerose múltipla e artigo manufaturado
RU2007147426A (ru) * 2005-05-20 2009-06-27 Дженентек, Инк. (Us) Предварительная обработка биологического образца, взятого у индивидуума с аутоиммунным заболеванием
US8144978B2 (en) 2007-08-01 2012-03-27 Tandent Vision Science, Inc. System and method for identifying complex tokens in an image
KR101041914B1 (ko) * 2008-06-26 2011-06-15 부산대학교 산학협력단 셀레늄에 의해 탈분화된 세포, 이의 제조방법 및 이의 용도
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法

Also Published As

Publication number Publication date
AU2003301079C1 (en) 2018-03-08
NO20053435L (no) 2005-08-31
RU2005122448A (ru) 2006-03-20
SI1572744T1 (sl) 2010-09-30
HRP20050649A2 (en) 2005-12-31
BR0316779A (pt) 2005-11-01
EP1572744A2 (en) 2005-09-14
IL168754A (en) 2011-09-27
WO2004056312A3 (en) 2005-05-26
NZ566907A (en) 2009-10-30
TW200501982A (en) 2005-01-16
US7799900B2 (en) 2010-09-21
CR11367A (es) 2010-07-23
JP2009159950A (ja) 2009-07-23
AR093046A2 (es) 2015-05-13
RS20050467A (en) 2007-08-03
JP5885457B2 (ja) 2016-03-15
TWI335821B (en) 2011-01-11
PL212899B1 (pl) 2012-12-31
CY2018009I1 (el) 2018-06-27
MXPA05006511A (es) 2006-02-17
CY2018009I2 (el) 2018-06-27
ES2347241T3 (es) 2010-10-27
KR20070055625A (ko) 2007-05-30
US20060034835A1 (en) 2006-02-16
ES2633311T3 (es) 2017-09-20
US20060024300A1 (en) 2006-02-02
UA89350C2 (uk) 2010-01-25
EP1944320A1 (en) 2008-07-16
EP2301966A1 (en) 2011-03-30
PL377328A1 (pl) 2006-01-23
CL2008003323A1 (es) 2009-03-06
SI2289936T1 (sl) 2017-10-30
CA2507898A1 (en) 2004-07-08
BE2018C021I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2023-03-07
RS20100366A (en) 2011-04-30
US20190071511A1 (en) 2019-03-07
AU2003301079B2 (en) 2011-06-23
MA27704A1 (fr) 2006-01-02
PT1572744E (pt) 2010-09-07
US20090155257A1 (en) 2009-06-18
HUS1800030I1 (hu) 2018-07-30
KR100910433B1 (ko) 2009-08-04
CY1110759T1 (el) 2015-06-10
IL214083A0 (en) 2011-08-31
NO338402B1 (no) 2016-08-15
AU2003301079A1 (en) 2004-07-14
AR042485A1 (es) 2005-06-22
RS51318B (sr) 2010-12-31
SG2013036975A (en) 2016-07-28
US20140154242A1 (en) 2014-06-05
KR20050086913A (ko) 2005-08-30
FR18C1023I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-07-13
US20170158773A1 (en) 2017-06-08
HRP20050649B1 (hr) 2016-06-17
BRPI0316779B8 (pt) 2023-02-28
JP4351674B2 (ja) 2009-10-28
BRPI0316779B1 (pt) 2020-04-28
HU227217B1 (en) 2010-11-29
EP1572744B1 (en) 2010-06-09
ATE470675T1 (de) 2010-06-15
FR18C1023I2 (fr) 2019-05-17
CN103833854A (zh) 2014-06-04
CR7875A (es) 2008-11-07
US20220002430A1 (en) 2022-01-06
DK1572744T3 (da) 2010-09-20
EP2289936A1 (en) 2011-03-02
HUE035898T2 (en) 2018-05-28
DE60332957D1 (de) 2010-07-22
JP2012044997A (ja) 2012-03-08
CA2507898C (en) 2014-02-18
RU2326127C2 (ru) 2008-06-10
TW201000132A (en) 2010-01-01
EP2289936B1 (en) 2017-05-31
DK2289936T3 (en) 2017-07-31
AR072523A2 (es) 2010-09-01
EP3263596A1 (en) 2018-01-03
CN103833854B (zh) 2017-12-12
EP1572744A4 (en) 2006-07-12
JP2006517399A (ja) 2006-07-27
HK1074208A1 (en) 2005-11-04
HUP0500954A2 (en) 2007-09-28
WO2004056312A2 (en) 2004-07-08
US8562992B2 (en) 2013-10-22

Similar Documents

Publication Publication Date Title
US20220002430A1 (en) Immunoglobulin variants and uses thereof
CN100460421C (zh) 免疫球蛋白变体及其用途
AU2017202590A1 (en) Immunoglobulin variants and uses thereof
HK1156047A (en) Immunoglobulin variants and uses thereof
HK1154871A (en) Immunoglobulin variants and uses thereof
HK1154871B (en) Immunoglobulin variants and uses thereof
HK1074208B (en) Immunoglobulin variants and uses thereof
HK1120058A (en) Immunoglobulin variants and uses thereof
HK1129406B (en) Immunoglobulin variants and uses thereof
HK1129406A (zh) 免疫球蛋白變體及其用途
HK1129405A (en) Immunoglobulin variants and uses thereof
HK1129407A (en) Immunoglobulin variants and uses thereof